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ABSTRACT 
 
Cardiovascular disease has emerged in developing countries and becoming the leading cause 
of death recorded. Many scientific studies have been conducted in order to understand the 
specific mechanism on how atherosclerosis develop, searching for the real culprit that 
responsible in the progression of the disease and suggesting the possible prevention to 
overcome this problem. This piece of work examined and revealed the mechanism of action 
on how secondary metabolites that has been isolated from Malaysian local plants which have 
the properties to impede the action of cholesteryl ester transfer protein (CETP) in order to 
prevent the atherosclerosis. Preliminary results of the crude plant extracts from the initial 
screening showed positive results. A similar trend of inhibition can be obtained for twigs and 
leaves extracts of Garcinia atroviridis and Garcinia parvifolia. Ethanol extracts of fruit parts 
of Garcinia atroviridis give IC50 of 19.28 ± 0.021 mg/ml which shows the highest inhibitory 
compared to the other extracts of other plant parts.  The remarkable results that are obtain 
from fruit rinds of Garcinia atroviridis do give some hints that the secondary metabolites that 
are present  might have the ability to inhibit CETP. Based on literature review, it is postulated 
hydroxycitric acid (HCA) might be responsible for inhibiting CETP activity and HCA has 
been selected for further studies. Kinetic studies have been employed in this piece of work in 
order to see the types of inhibition that HCA possess against CETP. The kinetic study has 
revealed that HCA is a noncompetitive inhibitor because of the Km (-0.12) that is unchanged 
for every substrate and the Vmax is increased when the concentration of the inhibitor 
increase.  Further in-silico works such as molecular docking and molecular dynamic has been 
implemented as well in order to see the interaction and mechanism of action between HCA 
and CETP. The molecular docking work has revealed that HCA binds to the same side as 
torcetrapib does and the RMSD obtained was 2.703Å. Molecular dynamics has been 
vii 
 
employed as well in order to see the extensive structural and functional analysis and also to 
evaluate the strengthness of the complex between HCA and CETP.  The complex were found 
to be stable due to the existence of the hydrogen bonding to SER230 and the overall RMSD 
reading are between the range of 0.8Å, 2.4Å and 3.2Å. Overall, this work are pioneering and 
pave the way for further studies in establishing a new chemical template form of natural 
products for CETP research with an objective to extend the scope of work into in-vivo studies 
and x-ray crystallography in order to enable us to understand the mechanism of action in 
protein level. The in-silico studies in this work provides a preliminary understanding on the 
structural basis of CETP structure and its active sites which could accommodate the exact 
template of chemical molecule. With this new understanding, an inhibitor drug which are 
effective with lesser side effect, targeting atherosclerosis could be developed.  
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Chapter 1: Introduction 
Cardiovascular disease (CVD) that involves the diseases of the heart and circulatory system 
remains the leading cause of death in worldwide which affecting almost 4.1 million deaths 
per year (Nichols et al., 2013).  
 
CVD epidemic that has emerge in the developing countries during the past two or three 
decades contributes a greater share to the global burden of CVD provides less public 
response even within the effected countries (Mathers & Loncar, 2006). The increase in the 
rate of CVD is due to the economic transition, industrialization and globalization which 
change the lifestyle of people in those developing countries which promote heart disease. 
Over the previous decade or more, the predominance of conventional danger components for 
atherosclerotic cardiovascular infections has been expanding in the major developing 
countries, including China and India, with resulting increments in the rates of coronary and 
cerebrovascular occasions (Celermajer et al., 2012). In Malaysia, the total deaths caused by 
CVD increased from 32% in 2010 to 36% in 2014 (WHO,2011; WHO,2015). Specific 
difficulties in tending to the expanding weight of CVD in Malaysia incorporate low spending 
plans for wellbeing (counting for screening, anticipation, and treatment), and also the training 
and expertise blend of the wellbeing workforce. 
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Figure 1 a) The proportional mortality rates in Malaysia for 2010 b) The proportional 
mortality rates in Malaysia for 2014 (WHO,2011;WHO,2015) 
a) 
b) 
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Elevated blood cholesterol level especially low-density lipoprotein cholesterol (LDL-C) is 
correlated with a higher risk of cardiovascular disease events such as heart attack, stroke and 
heart failure.  LDL is also known as a primary carrier of cholesterol, transport cholesterol to 
cell where it is being used in the cell membrane (Crockett, 1998) and for the  synthesis of 
steroid hormones, vitamin D, and bile acid . Cells take up cholesterol by a process called 
receptor-mediated endocytosis. LDL binds to a specific LDL-receptor that exposed to the cell 
surface and is internalized by endocytosis. The endocytic vesicle then pinches into two 
smaller vesicles; (1) containing free LDL (2) empty receptors. The vesicles which contain 
LDL fuses with a lysosome to form secondary lysosome. The enzyme of the lysosome will 
then release free cholesterol to the cytosol. The empty receptors will return to and fuses with 
the plasma membrane, turning inside out as it does (exocytosis) and later it will be reuse 
again. The excessive transportation of LDL throughout the human body can cause cholesterol 
build-up in the arteries. This build up can eventually lead to an arterial blockage that is being 
known as atherosclerosis. The early stage of atherosclerosis started when atherosclerotic 
plaque forms when LDLs are accumulated in the arterial intima and become oxidized over 
time gives rise to the narrowing of arteries, rupture, and stenosis or closure of the lumen, 
clotting and finally will lead to sudden death if untreated.  
 
High-density lipoprotein cholesterol (HDL-C) is also known as “good cholesterol” because it 
is shown in several epidemiological studies that high levels of HDL-C are associated with 
reduced levels of CVD and low-level HDL-C are associated with high risk of CVD . HDL 
acts as a scavenger, which protects the arteries by removing LDL cholesterol away from the 
arteries and back to the liver. Cholesterol will then be metabolized and passed from the body. 
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The progression of CVD will cause serious health condition; therefore, it is important to 
diagnose these diseases as early as possible. Several tests and diagnosis have been developed 
over the years including electrocardiogram, echocardiogram, stress test, cardiac 
catheterization or angiogram, heart scan and magnetic resonance angiography (MRA). But 
the most effective way is by having healthy ways of lifestyle such as reduced alcohol intake, 
quit smoking, exercise regularly, reduce stress and having a healthy and balanced diet. 
 
The treatments of CVD are the same for both genders (men and women). Treatments that 
have been available nowadays may include changing in lifestyle, medication, surgical 
procedures and rehabilitation. 
 
Lowering the LDL-c levels in the blood has been a major target for research in order to 
prevent the progression of CVD. Based on this approach numerous drugs have been 
developed in order to prevent CVD, especially statin. However, some controversial issue 
arises based on this approach whereby CVD is a multifactorial disease and increase in LDL-c 
level cannot be solely be blamed as the main factors. Therefore, the research strategies aimed 
on increasing HDL since HDL is identified as an independent risk factor and it is seem to be 
promising target in fighting against CVD. 
 
One of the ways to increase HDL-C level in human bloodstream is by inhibition of 
cholesteryl ester transfer protein (CETP). CETP is a hydrophobic plasma protein that is 
mainly secreted in the liver and basically travels in the plasma and mainly bound to HDL . It 
transfers cholesterol esters (CE) and triglycerides (TGs) between HDL and other lipoprotein 
particles that results in equilibration of lipids in lipoprotein fractions. Hence inhibition of 
CETP indirectly increases HDL-C levels (Barter et al, 2007). Due to this nature, HDL is 
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rapidly being catabolized and most of the cholesterol are transported through LDL. Therefore 
by targeting the inhibition of CETP has become an attractive strategy to reduce the CVD.  
 
One of the novel strategies has led to the discovery of novel CETP inhibitors torcetrapib 
which successfully inhibits CETP activity. However, torcetrapib caused controversy against 
its clinical trials which increased blood pressure and mortality rate (Barter,2009). Due to this 
problem, all the clinical trials that are associated with torcetrapib are terminated. This does 
not cause researcher to give up finding new drugs that can inhibit CETP and more studies and 
techniques have been implemented in searching for the potent inhibitor of CETP.  
 
Investigation into unexplored natural product is essential in the quest to discover novel 
therapies for CVD. Garcinia atroviridis is used in traditional Malaysian folklore medicine as 
a cholesterol-lowering agent and yet there is no evidence that shows this plant would directly 
inhibits CETP. Therefore the ultimate purpose of this work is to study the inhibitory 
interaction between CETP and Garcinia plant species and to gain more detailed information 
of what compound that can inhibit CETP. The interaction between compound of interest and 
CETP activity are studied using molecular docking and dynamic simulation, which offer a 
possibility to examine detailed knowledge on an atomic scale. The obtained results can be 
used in the future for the development of new inhibitor agents against the progression of 
CVD. 
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1.1 Aims and Objective 
The aim of this research was to evaluate the potential Malaysian rainforest plants that may 
possess inhibitory activity against Cholesteryl Ester Transfer Protein (CETP) and further 
analysis of the inhibitory activity of the compound using in-silico approach. 
 
The objectives include:  
1) To collect and identify potential Malaysian Rainforest plant. 
2) To study the inhibitory interaction between CETP and Garcinia species in order to 
have an idea of what compound that can inhibit CETP. 
3) To evaluate the kinetic properties of compound of interest and CETP. 
4) To prove the presence of HCA in UNMC 78F ethanol extract. 
5) To study the interaction between compound of interest with CETP using molecular 
docking and dynamic simulation. 
6) To study the Structural Activity Relationship (SAR) of HCA analogues through 
molecular docking.  
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Chapter 2: Literature Review 
2.1 Prevalence of cardiovascular diseases 
Cardiovascular disease (CVD) includes a wide range of disorders; diseases of the vasculature, 
diseases of myocardium, diseases of hearts electrical circuit and congenital heart disease  and 
are among the leading cause of death in most western countries. CVD become a global 
burden to the economies especially most of the money are invested to the prevention of CVD 
and treatment of CVD. Besides, incapacity of works might be affecting the economics since 
the increasing rates of death due to CVD before the age of 65. Based on Nichols et al., 
(2013), it accounts 680,000 deaths each year in Europe making it the main cause of death 
before 65 years of age.  
 
Atherosclerosis is the most important cause for CVD and it is a multifactorial disease. 
Atherosclerosis is a disease in which the arteries narrow down due to the formation of 
atherosclerotic plaque. This will eventually blocks the oxygenated blood flow to the tissues. 
This may lead to ischemia, a condition that is lack of oxygen in the blood or myocardial 
infarction (heart attack), which then might cause death. The development of atherosclerosis 
might take years to progress and has usually proceeded far before the first symptom appears. 
Therefore it is important to focus on different treatment and prevention strategies to reduce 
the risk of CVD. 
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2.1.1 Cardiovascular diseases in general 
CVD disease is a term that refers to more than one disease in circulatory system which 
includes heart and blood vessel. There are 6 types of cardiovascular disease; 1) ischemic 
heart disease; 2) cerebrovascular disease; 3) peripheral vascular disease; 4) heart failure; 5) 
rheumatic heart disease and 6) congenital heart disease (WHO, 2016). 
There are many risk factors that may attribute to the development of CVD and can be divided 
into modifiable risk factors and non-modifiable risk factor. The modifiable risk factors 
includes hypertension or high blood pressure, usage of tobacco, raised in blood glucose levels 
or diabetes, physical inactivity, unhealthy food consumption, raised in the level of blood 
cholesterol and overweight or obesity (Barnes, 2013). In addition to modifiable risk factor, 
there are some risk factor that cannot be altered such as age, gender and family history of 
CVD (Hobbs, 2004).  
 
The most important risk factor is the raised cholesterol in blood circulation which attribute to 
over one third of ischemic heart disease in the world (Birtcher and Ballantyne,2004) . The 
general guidelines to identified those with high risk of developing CVD is those who has 
LDL-C of less than 2.0 mmol/L (Reiner et al., 2011) . 
 
It is important to have proper risk assessment to validate whether the people are in which 
category of CVD; low risk, intermediate risk or high risk individual. Cardiovascular risk 
assessment is beneficial especially to primary health care providers in order to detect patient 
in order to provide proper treatment. Several studies have also shown that the benefits of risk 
assessment are maximized when it is directly communicated to the patient and the patients 
are devoted to the prescribed therapy (Cooney et al., 2009; Grover et al., 2007; Grover et al., 
2007; Ebrahim et al., 2011). 
9 
 
 
Figure 2 Risk stratification by Framingham Risk Score and phenotype. Framingham 
Risk Score is a risk assessment tool for estimating a patient’s 10 year risk of developing 
cardiovascular disease. (Anderson et al., 2013). 
 
Over the past decade, statins or 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) 
inhibitor have appear to be a primary therapy and it is also shown to reduce the level of CVD 
by 25% to 35% by lowering the LDL level (Baigent et al.,2010). Statin acts as an inhibitor of 
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the enzymes which are 
responsible in catalyzing the rate-limiting step of cholesterol biosynthesis (Medina and 
Krauss, 2009).  
Stratify by Risk 
Features
Low Risk  
LDL more than 
5 mmol/L
LDL less than 5 
mmol/L
Intermediate 
Risk
High Risk
Health 
behaviour 
modification.  
Statin therapy
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Figure 3 Cholesterol is the end product of the mevalonate pathway. The initial phase in 
cholesterol biosynthesis is the generation of a 3-hydroxy-3-methyl-glutaryl CoA (HMG-
COA) from acetyl-CoA units. At that point, HMG-CoA is converted to mevalonate by 
the activity of HMG-CoA reductase on endoplasmic reticulum membrane. This is the 
main restricting rate response in cholesterol synthesis and becoming the target of statin. 
Mevalonate is then transformed to isopentenyl pyrophosphate and dimethylallyl 
pyrophosphate which later producing pyprophosphate and squalene.  Production of 
lanosterol involves the cyclization and oxygenation of squalene. And lastly the 
cholesterol will be produced when the lanosterol undergoes reduction process (Cortes et 
al., 2013) 
11 
 
Statin imitates the HMG-CoA molecule and it competes for the binding to the HMGCR 
enzyme. This inhibition blocks the mevalonate pathway which is one of the cholesterol 
producing precursor. Statin alters the conformation of the enzyme when it binds to its active 
sites which further prevents the enzymes to attain their own functional structure (Corsini et 
al, 1999). This will then lead to the increase in the number of hepatic LDL-receptor which 
determines the decline in the circulation of LDL and its precursor such as IDL (intermediate 
density lipoprotein) and VLDL (very low density lipoprotein) (Sehayek  et al.,  1994). The 
decrease in LDL-C by statins are dose-dependent study on statin indicate that statins does 
gives rise to ‘pleiotropic effect’ such as improving endothelial function, enhancing the 
stability of atherosclerotic plaques, decreasing oxidative stress and inflammation and an 
inhibiting the thrombogenic response (Davignon, 2004) . 
 
Statin has remained as the first-line therapy for managing the high level of low-density 
lipoprotein (LDL) cholesterol in the blood of patient that have been diagnosed with CVD. 
Since atherosclerosis is a multifactorial disease and the current medication is not enough to 
prevent the progression of CVD, the therapies concerning to increase HDL-C level has to be 
improved.  
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SIMVASTATIN    PRAVASTATIN  
Figure 4 Various chemical structures of statin 
 
The use of niacin (nicotinic acid:Vitamin B3), cholesterylamine and fibrates has been use in 
clinical trials in order to increase HDL-C levels (Boden et al,  2011). Niacin acts by inhibits 
the secretion of VLDL particles, increase lipoprotein lipase activity and decrease triglyceride 
levels and it has been proven to increase HDL-C levels by 15% to 35% (Taylor et al., 2004). 
Gemfibrozil, belongs to group of drugs known as fibrates that has been tested, shown an 
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increase in HDL-C levels by 10-15% (Frick et al., 1987) via the hepatic expression of the 
main HDL apoliproteins A-I and A-II (apoA-1 and ApoA-II) (Staels et al., 1998; Kumar et 
al., 2013). The results from these clinical trials are promising but yet more therapies need to 
be developed. One of which the alternative strategy is to increase the HDL-C level is by 
focusing into inhibition of CETP. 
 
Health behaviour intervention remains the keystone of any disease prevention which also 
includes the prevention of CVD (Stuart-Shor et al., 2012; Prochaska and Prochaska, 2013). 
Data from the INTERHEART study revealed that, in addition to the traditional risk factors 
which are abnormal lipids, hypertension and diabetes, abdominal obesity, dietary patterns, 
alcohol consumption, physical inactivity, psychosocial factors and smoking are considered as 
modifiable risk factors for both sexes and all ages worldwide (Yusuf et al., 2004) . 
 
Nutritional therapy is the most essential elements of the health behavior interventions and its 
objective is to improve lipid profile and reduce the risk of CVD. Nutritional therapy is also 
being used in a weight management program. In order to maintain healthy body weight, a 
balance diet provides all the essential nutrition which balance out the calories intake and 
number of calories that is being used or “burns-off”. Sufficient physical exercise also 
contributes in the prevention of CVD. Several study has presented the benefits of routine 
exercise in maintaining healthy lifestyle and prevention of CVD (Thompson et al., 2003; 
Myers, 2003) .  
 
Psychological factors which includes stress is also modifiable risk factors for CVD. Stress 
management is important, not only to reduce risk of CVD but to optimize the quality of life. 
The INTERHEART study revealed that stress is one of the risk factor in the development of 
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CVD which shows patients with depression have a worse prognosis (Yusuf et al., 2004). 
Smoking cessation or quitting smoking is the process of discontinuing the addiction of 
tobacco smoking. This is important in the health behaviour intervention as smoking caused 
detrimental effects on lipid profiles (Khurana et al., 2000). Based on Ambrose & Barua 
(2004), there is a linear and dose-dependent correlation between the number of cigarettes 
smoked per day and the increase in CVD risk. Several pharmacological treatment has been 
developed to help people to quit smoking includes nicotine-based medicine, transdermal 
nicotine patch, nicotine gum, nicotine lozenge, nicotine nasal spray, nicotine inhalant, 
bupropion and vernicline (Schmelzle et al., 2008). Not only the development of treatment, 
help support services also being offered by expert in order to boost the chance of quitting 
smoking (Hughes, 2003). 
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2.2 Atherosclerosis 
2.2.1 Pathogenesis of atherosclerosis 
Atherosclerosis is a multifactorial disease which caused by genetic and environmental 
factors. Basically the names of atherosclerosis derives from Greek words “sclerosis” which 
means hardening and “athere” bring the meaning of gruel (accumulation of lipid). 
 
The evolution of atherosclerosis starting from arterial wall lesions which is centered by 
accumulation of lipids and followed by inflammatory response. The changes of the 
development of atherosclerosis are concisely being described in the next paragraph. 
 
 
 
 
 
 
 
 
 
Figure 5 Schematic diagram of the development of atherosclerotic plaque. This diagram 
shows the involvement of oxidized low density lipoprotein (Ox-LDL), endothelial cell 
injury and proliferation of vascular smooth muscle cells (SMC). MAP in this diagram 
refer to mitogen activated protein (Singh et al., 2002) 
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2.2.1.1 Early Fatty Streak Development 
The normal artery contains three layers, the innermost layer named as intima consists of an 
extracellular connective tissue matrix which is covered by monolayer endothelial cell. The 
middle layer, named as media, contains resident smooth muscle cells (SMC) and the outer 
layer named as adventitia consists of fibroblasts and mast cells. The initial step occurs when 
the level of LDL leaves the blood increases and enter intima, accumulation will occur. The 
important event in the initiation of atherosclerotic lesion is the endothelial injury which will 
activated the inflammatory cascade. 
 
Figure 6 Three layers of coronary artery (Libby et al., 2011) 
 
The inflammatory cascade of atherosclerosis initiated when the expression of adhesive 
protein (vascular cell adhesion molecules [VCAM-1]) increases the recruitment of monocytes 
and T-cells as response to the endothelial injury. Monocyte chemo attractant protein (MCP-1) 
also being released by leukocytes which amplify the inflammatory cascade by recruiting 
more leukocytes, activates leukocytes in the middle layer of artery named as media which 
cause proliferation of smooth muscle cells. 
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Once monocytes have attached to the endothelium, chemokines will be produced in the 
underlying intima. In order to stimulate the migration through the endothelial surface into the 
media, activated matrix metalloproteinase (MMP) also being release to degrade the 
connective tissue matrix . 
 
Upon entering the intima, monocytes differentiate into macrophages by the local release of 
macrophage colony stimulating factor (MCSF) and express at high level of scavenger 
receptors and toll like receptor. The scavenger receptor that is being expressed by 
macrophages on their plasma membrane uptake the oxidized LDL that is accumulate in the 
inside of blood vessel wall and develop into foam cells. Toll like receptors (TLR) promotes 
atherogenesis through the interruption of endothelial cell integrity and normally initiate the 
inflammatory responses by producing inflammatory cytokines proteases and cytotoxic radical 
molecules (Tobias & Curtiss, 2007). The onset of atherosclerosis is believed to start when the 
lipid accumulation is described as confluent extracellular lipid pools and decreasing in 
cellularity of extracellular lipid cores (Insull, 2009). 
 
18 
 
 
Figure 7 Series of lesion development (A) The expression of VCAM-1 (adhesive protein) 
causing the leucocytes to adhere to endothelium as the initial stage of atherosclerosis (B) 
Leucocytes migrate to the endothelial barrier and begin to accumulate (C) 
Macrophages releases cytokines and cross the barrier from endothelial surface into 
media of the vessel (D) Accumulation of foam cells indicates clinical prognosis of 
atherosclerosis progression (E) Advanced stage of atherosclerosis in which it needs 
medical intervention  whereby it can be characterized by intimal narrowing, many foam 
cells, neovascularization and flow limiting narrowing. (Crowther, 2005) 
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2.2.1.2 Progressive atherosclerotic lesions. 
 
Early fibroatheroma occurs as results of pathologic intimal thickening. The accumulation of 
numerous number of cells, TLR which are also activated the inflammatory cells and other 
natural cells in the arteries may cause early fibroatheroma. Plaque that is rich with smooth 
muscle cells excrete proteoglycan will cause lipid binding and further accumulation of 
extracellular lipid. Some factors may contribute to the apoptotic death of macrophages and 
SMC which later provokes more serious inflammation (Bentzon et al., 2014).  
 
 
Figure 8 Intimal Thickening, EL indicates extracellular lipids. Intimal thickening or 
also known as intermediate lesion is characterized by non-apparent of true necrosis, no 
cellular debris, some lipid may present in the lesion but scattered. The fibrous cap that 
is overlying in the lipid region contains lot of smooth muscle cells and proteoglycan. 
Some scattered macrophages and lymphocytes may likewise be available, however these 
are generally meager. (Virmani et al.,  2000) 
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Figure 9 Early fibroatheroma, NC indicates necrotic core. The more authoritative lesion 
or also known as fibrous cap atheroma. It is traditionally demonstrates a “genuine” 
necrotic core which contains cholesteryl ester, free cholesterol, phospholipids and 
triglycerides. The fibrous cap comprises of smooth muscle cells in a proteoglycan – 
collagen matrix with a variable number of macrophages and lymphocytes. The media 
underneath the plague is frequently thin.  (Virmani et al., 2000) 
 
Increase accumulation of extracellular lipid may cause early necrosis. This induces the 
distortion of normal construction of intima until it is fully disrupted. This enlarging pools of 
lipid-rich necrotic cores takes up 30% to 50% of arterial wall volume (Burke et al., 2001). 
Fibrous cap is made of a layer of fibrous tissue which is found in the intima under the 
endothelium at the blood interface which forms fibrous plaque lesions.  
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Figure 10 Examples of coronary lesions via virtual histology. Using the virtual histology, 
specific color code were assigned for each tissue component, fibroua (dark green), 
fibrofatty (light green), necrotic core (red) and dense calcium (white) (García-García et 
al., 2009) 
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2.2.1.3 Thin cap atheroma: A vulnerable plaque 
Thin-cap atheroma contain a thin, fibrous cap (less 65μM thick) (Virmani et al.,, 2003) and 
infiltrated by macrophages and lymphocytes. This thin cap fibroatheroma are being called as 
‘vulnerable plaque’ due to the thickness which indicates instability and susceptible to rupture 
(Virmani et al., 2003). This lesion having the potential to become thrombogenic and 
produces a thrombus which extends into the arterial lumen (Muller & Tofler, 1992). 
 
Figure 11 Illustration of Thin-Cap fibroatheroma (Virmani et al., 2000). 
 
This plaque may cause enlargement and might grow into media and adventitia and distort 
them. Intramural haematoma might be develop which is cause by a spontaneous rupture of 
new vasa vasorum (fragile vessels of endothelium), may leak and produce hemorrhage within 
the arterial wall which later provokes increased in fibrous tissue (Sundt, 2007). 
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Figure 12 Fibrous cap atheroma with hemorrhage. This lesion contains red blood cells 
and fibrin. The fibrous cap is mature and profound inside the intima are territories of 
calcification. (Virmani et al., 2000) 
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2.2.1.4 Lesion enlargement 
The plaque rupture as being described above have the ability to heal silently by forming 
fibrous tissue, extracellular matrix which consists of proteoglycans, collagen but it is prone to 
rupture again with the formation of thrombus (Wal & Becker, 1999). 
 
Figure 13 Illustration of plaque rupture where orgTh is organizing thrombus, NC is 
necrotic core and Th is acute thrombus. Rupture/Erosion: The past rupture site 
overlying a necrotic centre is distinguished by the arrowhead, an acute thrombus (Th) 
from plaque erosion possesses into the lumen. The fibrous cap appears to be thick and 
the rupture has happened in the centre of the cap. Rupture/Rupture: Repetitive plaque 
rupture. Multiple rupture site are appeared by arrowheads. NC* indicates the second 
necrotic centre and an organizing thrombus resulting from the consequent rupture is 
distinguished by the arrow.  (Virmani et al., 2000) 
 
Calcification will occur in the wall of artery may form as small aggregates at first and later as 
large nodules. These nodules may become sites of thrombosis when it is being exposed due 
to the plaque rupture. Stenosis (blockage of epicardial coronary vessels) may form due to the 
increase mass of some plaques and later will cause myocardial ischemia which is the result of 
oxygenated blood restriction in the heart muscles (Ibañez  et al., 2009). 
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Figure 14 Calcified nodule, where TH indicates luminal thrombi and FC is thin fibrous 
cap. Calcified nodules are plaques with luminal thrombi indicating calcific nodules 
projecting into the lumen through a disrupted thin fibrous cap (FC). There is 
nonappearance of an endothelium at the site of the thrombus, and inflammatory cells 
(macrophages, T lymphocytes) are truant. (Virmani et al., 2000). 
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2.2.1.5 Summary of development of atherosclerosis 
Atherosclerosis, infrequently called "furring up the arteries," happens when fat (cholesterol) 
and calcium develop inside the lining of the artery wall, framing a substance called plaque. 
After some time, the fat and calcium development limits the artery and blocks blood flow 
through it. The summary of the development of atherosclerosis can be depicted from the 
figure below. 
 
 
 
 
Figure 15 Schematic diagram of general concepts of the development of atherosclerosis. 
Atherosclerosis occurs basically from the intimal thickening and intimal xantoma which 
then leads to the formation of thin fibrous cap atheroma. This will eventually cause 
rupture or erosion and further development of fibrocalcific plaque. ACS which 
indicates acute coronary syndrome is a complication due to decrease of blood flow in 
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the coronary arteries which resulting from the formation of thrombosis.  (Virmani et al., 
2000) 
2.2.2 Animal model of atherosclerosis 
 
An animal model has played a major role in the search for new therapies against 
atherosclerosis. The first breakthrough by Russian Scientist, Alexander Ignatowski in 1908 
demonstrated that atherosclerosis can be induced in rabbits by feeding them milk and egg 
yolks (Konstantinov & Jankovic, 2013). Since this breakthrough, animal models have 
valuable information regarding diagnosis and therapeutic strategies for atherosclerosis. 
Several animals models had been used such as mice, rats, guinea pigs, hamsters, avian, swine 
and non-human primates and there are several advantages, and disadvantages should be taken 
care of. 
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Table 1 Advantages and disadvantages of various animal model of atherosclerosis 
Species Advantages Disadvantages Sources 
Rabbit Expresses 
Cholesteryl 
ester transfer 
protein 
Cholesterol-
sensitive 
Forming large 
foam cells 
Deficiency in 
hepatic lipase 
Bocan  et al., 1993; 
Nordesgaard and Zilversmit, 
1988; Shiomi and Ito, 2009; 
Buja et al., 2983; Atkinson et 
al.,  1989; Shiomi et al., 1992; 
Brousseau, 1999 
Pig Human-like 
lipoprotein 
profiles 
Moderately 
cholesterol 
sensitive on 
normal diet 
Large tissue 
availability due 
to the size 
Expensive 
No genetic 
modification 
available 
Skold et al., 1966; Reiser et 
al., 1959; Koskinas et al., 
2010; Gerrity et al., 2001; 
Prescott et al., 1991; 
Checovich et al., 1988 
Mice Easy to breed  
Large size of 
litters 
Easy for genetic 
manipulation 
Low cost 
Formation of 
atherosclerosis 
in short period 
Limited tissue 
availability due 
to small size 
No coronary 
lesions 
Wild-type strain 
is relatively 
atherosclerosis 
resistant 
Yang et al., 2010; Teupser et 
al., 2006; Smith et al.,  2003 
Nonhuman 
primates 
Develop 
coronary lesions 
 
Expensive 
No genetic 
modification 
available 
Portman and Andrus, 1965; 
Wolfe et al., 1994; 
Vesselinovitch et al., 1974; 
Davis et al, 1984; Mott et al., 
1992 
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The most widely used animal species that has been used in atherosclerosis research are 
mouse although there are some limitations. Mice have been used in atherogenesis research 
due to the ease of making genetic manipulation. Several transgenic mice strains have been 
develop for atherosclerosis research such as the first genetically mouse with the apoE gene 
and he two mouse strains that are most as often as possible being utilized as a part of 
atherosclerosis experimentation are apoE-/ - model and LDL-/ - model (Plump et al., 1992; 
Zhang et al., 1994). Both of these strains are different in their dietary needs for developing 
atherosclerosis. The development of complex vascular lesion can be induced in apoE-/- by 
giving normal low-fat rodent chow, and high fat high cholesterol western type diet (WTD), 
and the lesions develops are comparable to human lesions. A noteworthy hindrance of 
utilizing this model is that the plasma cholesterol is generally being conveyed by lipoprotein 
remnants contrasted with LDL that turn into the major carrier of plasma cholesterols in 
human (Whitman, 2004). 
 
The other most favoured of mice strain for atherosclerosis research is LDLR-/- due to the 
function of LDLR that influences the uptake of clearance of LDL (Ishibashi et al., 1993). The 
developments of vascular lesions are slow when it is being fed by low-fat chow diet. Despite 
the limitations of the mice model, the applicability of the mouse findings to human model is 
to catalog the biological mechanisms of atherogenesis. An exhaustive comprehension of the 
animal models utilized and complete analysis must be approved so that the information can 
be extrapolated to people. All in all, animal models for atherosclerosis are important in 
enhancing our comprehension of cardiovascular disease and developing new pharmacological 
treatments.  
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2.3 Lipoprotein and Lipid metabolism 
Lipoproteins are water soluble particles consists of lipids and proteins and synthesized 
mainly in the liver and intestines. Lipoproteins aggregate are being classified based on their 
density when subjected to ultracentrifugation such as chylomicrons (CM), VLDL (very low-
density lipoprotein), LDL (low-density lipoprotein) and HDL (high-density lipoprotein) 
(Chasman et al., 2009).  
 
Figure 16 Major lipoprotein classes and their density (Saland & Ginsberg, 2007) 
 
The function of lipoproteins as a transporter for hydrophobic triglycerides (TG) and 
cholesterol in the circulation. Lipoproteins are highly dynamic particles whereby it undergoes 
constant modification including enzymatic reaction, facilitated and spontaneous lipid 
transfers, transfers of soluble apolipoprotein and conformational changes of the 
apolipoproteins in response to the compositional changes (Jonas et al., 1988; Jonas, 2002) 
 
The major routes of metabolism of lipoproteins involves; 1) exogenous pathway which 
involves in the uptake transportation of dietary lipid from intestine to peripheral tissues 2) 
Endogenous pathway which involves lipoprotein metabolism that are being synthesized in the 
liver and 3) reverse cholesterol transport (RCT) involves transportation of the cholesterol 
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from peripheral tissues back to the liver (Kwiterovich, 2000; Lippi & Guidi, 2000). All of 
these pathways which are an important target for drugs intervention will be discussed in the 
next following chapters. 
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2.3.1 Exogenous pathway 
Exogenous cholesterol which is secreted from intestinal cells are comprised of dietary uptake. 
Once the cholesterol is esterified, the cholesterol is being hydrolyzed forming free fatty acids 
and monoacylglycerols by pancreatic cholesterol ester hydrolase that is being produced by 
the exocrine pancreas. Free fatty acids and fat-soluble vitamins are then solubilized into 
micelles and absorbed by enterocytes.  
 
Once in the enterocytes, the free fatty acids underwent re-esterification into cholesterol ester 
by CoA: cholesterol acyltransferase (ACAT) and assembled with other lipids and 
apolipoprotein forming chylomicron (CM). CM will be released into the lymphatic system 
and further into the blood circulation via thoracic duct (Dawson & Rudel, 1999). In the 
circulation, CM are further hydrolysed forming chylomicron remnants by the help of 
lipoprotein lipase at the endothelial surface of vessels (Patsch, 1998). 
 
These chylomicron remnants are being discarded from the circulation by chylomicron 
remnant receptor on the liver which is known as LDL-like receptor protein (Mahley, 1996). If 
the CM remnants are small enough, it can pass through the endothelial surface of the arterial 
wall and contribute to atherogenesis by forming plaque formation (Kirchmair et al., 1995). 
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2.3.2 Endogenous pathway 
Liver is the primary organ responsible for the synthesis of lipid, which regulates plasma 
levels and lipid homeostasis and this is the origin of the endogenous lipid at which some of 
the TG and cholesterol are being synthesized at the liver. Lipid endogenous pathway involves 
the transportation of lipids from liver to peripheral tissues. The liver synthesizes VLDL 
which consists of cholesterol and TG and requires apoliprotein B-100 (Gotto et al., 1986). 
Apoliprotein B-100 contains domains that is responsible for cellular uptake of cholesterol by 
the LDLR-mediated pathway (Johs et al., 2006). 
 
In plasma, VLDL are hydrolyzed into free fatty acid and glycerol by lipoprotein and cofactor, 
apolipoprotein C-2 (Fielding, 1978; Packard et al., 2000). This resulting in the production of 
VLDL remnants and IDL. IDL undergo alteration with a detachment of the remaining TG 
and its substitution by cholesterol esters and removal of all the apolipoprotein accept Apo-B. 
TG in IDL will undergo further hydrogenation forming LDL by hepatic lipase. The removal 
of LDL is basically by the interaction of apolipoprotein B-100 with LDL receptor. Oxidation 
of LDL can further transport LDL to macrophage via scavenger receptors, CD36 and SR-A 
which appear on the surface of macrophage (Kwiterovich, 2000).  
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2.3.3 Reverse Cholesterol Transport 
Reverse cholesterol transport (RCT) by which extrahepatic (peripheral) cholesterol is 
returned to the liver for excretion in the bile and ultimately the feces (Glomset, 1968). RCT 
involves several steps which are 1) Transportation of cholesterol from peripheral cells to 
HDL or also known as cholesterol efflux 2) esterification of cholesterol within HDL by 
enzyme lecithin: cholesterol acyltransferase (LCAT) 3) cholesterol transfer to the apo-B 
containing lipoproteins 4) remodeling of HDL 5) HDL cholesterol uptake by the liver, kidney 
and small intestine via lipoprotein receptors. 
 
Figure 17 Overview of reverse cholesterol transport (RCT). The cardioprotective effect 
of HDL is attributed to its ability to remove excess cholesterol from artery wall 
macrophages. Two pathways which are being activated when macrophages acquire too 
much cholesterol involving the membrane ATP cassette reporters; ABCA1 and ABCG1. 
In the help of lessthin-cholesterol acyltransferase (LCAT) free cholesterol in nascent 
HDL is converted to cholesteryl ester which will generate a mature HDL particle. HDL 
will enter the circulation, and it transports back to the liver for excretion in the bile. 
One membrane protein on hepatocytes, SR-B1 will help to remove the cholesteryl ester 
from HDL. This will be converted back to cholesterol and bile acid and later will be 
excreted into the bile for excretion.(Heinecke, 2011) 
35 
 
2.3.3.1 Step 1: Transportation of cholesterol from peripheral cells to HDL (cholesterol 
efflux) 
 
Cholesterol that is derived from diets or other by-products synthesis in the liver or intestines 
is secreted by hepatocytes in the form of apoB-containing lipoprotein in a forward pathway to 
supply cholesterol to peripheral tissues (Cuchel & Rader, 2006). These lipoproteins are taken 
up by macrophages forming foam cell (Li & Glass, 2002). 
 
Cholesterol elimination from macrophages involves key regulator, ABC transporter A1 
(ABCA1) which helps to efflux forming free cholesterol (Oram & Vaughan, 2006). The 
binding of lipid pool apolipoprotein A-1 (ApoA-1) to ABCA1 transporter generate multistep 
process by which phospholipid and cholesterol are transferred to apoA-1 forming discoidal 
HDL (Hassan et al., 2007; Vedhachalam et al., 2007).  
 
The second ABCA transporter named as SR-B1 mediates selective uptake of HDL 
cholesterol by the liver. It collaborates with ABCA-1 by adding cellular lipids to the initial 
HDL particle forming mature HDL (Barter, 2003). 
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2.3.3.2 Step 2: Esterification of cholesterol within HDL by enzyme lecithin: cholesterol 
acyltransferase (LCAT). 
 
Within HDL, LCAT (lecithin – cholesterol acyltransferase) catalyzes the esterification of free 
cholesterol and phospholipid in HDL (α -activity) or TG-rich lipoproteins (β -activity) 
forming cholesterol ester and lysolecithin (Subbaiah  et al., 1994). LCAT plays an important 
role in the maturation of HDL-C from its nascent particles (Zannis  et al., 2006). 
 
The function of esterification of cholesterol in HDL is to allows accumulation of free 
cholesterol and to block reentry of cholesterol into peripheral cells (Yokoyama, 2000). 
 
2.3.3.3 Step 3: Cholesterol transfer to apoB containing lipoprotein 
In RCT pathway, CETP balances the redistribution and equilibration of lipoprotein within the 
plasma compartment. It mediates the transfer of HDL to VLDL and LDL (ApoB containing 
lipoproteins) in the exchange for TG. CETP is a hydrophobic glycoprotein that consists of 
476 amino acids (Tall, 1993). 
 
2.3.3.4 Step 4: Remodeling of HDL 
After the transfer mediated by CETP, hepatic lipase, and endothelial lipase reacts to complete 
the transfer of the remaining CE and TG in the HDL. Hepatic lipase is synthesized by 
hepatocytes that are secreted and bound to the extracellular matrix of endothelial cells of the 
liver (Rea  et al., 1993). 
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Hepatic lipase catalyzes the hydrolyzation of TG and phospholipids in VLDL remnants, 
LDL, and larger HDL2, promoting the remodeling of HDL into its smaller and denser HDL3 
particles (Connelly, 1999; Rye et al., 1999).  
 
Hepatic lipase also promotes the attachment of ApoA-1 from HDL particles which will then 
goes into periphery (Barrans et al., 1994; Clay  et al., 1992). Hepatic lipase also acts by 
releasing CE from HDL, which then will lead to the uptake by the liver. 
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2.3.3.5 Step 5: HDL cholesterol uptake by the liver. 
After transportation to the plasma compartment, next step of RCT is mediated by SR-B1 
where it transfers cholesterol from macrophages to the liver, SR-B1 is a member of scavenger 
receptor superfamily of proteins mediates the selective uptake of HDL-C towards the liver 
(Varban et al., 1998).  
 
The last steps of RCT are to eliminate cholesterol from the body. CE is being hydrolysed by 
neutral CE hydrolase to generate free cholesterol and will further secrete into the bile by the 
help of ABCBII or bile salt export pump. The function of ABCG5 and ABCG8 also take into 
accounts as both of these are obligate heterodimers which mediate plant sterols and 
cholesterol into bile (Yamanashi  et al., 2011). These bile products are then being eliminated 
from the body through intestines.  
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2.4 Role of HDL in atherosclerosis 
 
2.4.1 HDL and its anti-atherogenic properties 
 
HDL is the smallest in term of surface area (Stoke’s diameter = 5 to 17nm) hence provide the 
high density (more than 1.063g/mL) among the plasma lipoproteins which consists of several 
subpopulations which vary in sizes, charges, shape, density and composition of lipids. 
Apolipoprotein A-1 (Apo A-1) are the predominant HDL proteins, and it has the α - 
electrophoretic mobility when it migrates in agarose gels and this fraction is being labeled as 
α-LpA-I. HDL can also be fractionate by density into HDL2 and HDL3.  
 
The knowledge of anti – atheroprotective of HDL has been established since it is a 
straightforward process of over-supply of cholesterol to vascular cells and several other 
mechanisms that are being involved which will be discussed in depth in this chapter.  
 
There several studies indicates that HDL levels are inversely correlated with premature CVD 
(Barter et al., 2007; Gordon et al., 1989). HDL does possess anti-atherogenic properties, 
which have the ability to remove cholesterol from cells which is being described earlier in 
RCT pathway. The correlation of HDL as anti-atherogenic properties including: 
1) Anti-inflammatory activity and antioxidant activity 
2) Antithrombotic activity 
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2.4.1.1 Anti-inflammatory and antioxidant action of HDL 
Atherosclerosis is an inflammatory disorder that caused by an accumulation of macrophage 
and T-lymphocytes in the intima. The early stage of the inflammatory response is the 
adhesion of the monocytes to the endothelium mediated by vascular cell adhesion molecule -
1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin (adhesion 
molecules) (Cullen & Lorkowski, 2005). The monocytes are then being recruited to the 
subendothelial space by chemokine which is monocyte chemoattractant protein-1 (MCP-1). 
 
Based on some in-vitro studies, HDL inhibits the expression of these molecules (VCAM-1, 
ICAM-1, E-selectin) by inhibiting endothelial sphingosine kinase; an enzyme that is 
responsible in the NF-κb pathway and later will activates the expression of the adhesion 
molecule (Xia et al., 1999).  The inhibition of sphingosine kinase has further effect by 
inhibiting the nuclear translocation of NF- κb (Xia et al., 1999). 
 
Figure 18 HDL inhibites the cytokines-induced expression of endothelial cell adhesion 
molecules by inhibiting sphingosine kinase and hinder formation of adhesion protein 
synthesis  (Xia et al., 1999) 
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Due to the inhibition of sphingosine kinase, the reduction of activation of NF-κb may cause a 
reduction in oxidative stress level as well. This is because NF- κb is being activated by 
reactive oxygen species and being in an inactive state by low levels of NO (Robbesyn et al., 
2003). The ability of HDL as an inhibitor of reactive oxygen species causes the synthesis of 
NO and inhibit the activation of NF- κb may further contribute to the inhibition of the 
adhesion molecule expression. This mechanism explains the role of HDL as an anti-
inflammatory. 
 
HDL also plays their role as anti-atherosclerotic activity by reducing LDL oxidation (Barter 
et al., 2004). Oxidized LDL is known to be the potent inducer for MCP-1 expression during 
the progression of atherosclerosis plaque. Apo-A1 (apolipoprotein of HDL) has the ability 
remove lipid hyper oxides from LDL, and the byproducts are then being eliminated by the 
liver (Barter et al., 2004). HDL also contain an enzyme; named as paraoxonase which 
protects against oxidation of LDL in the artery wall (Mackness et al., 2004). 
 
A study comparing HDL with and without paraoxonase that was being incubated with 
endothelial cell line together with LDL-C. The results showed that HDL with paraoxonase 
significantly protect LDL-C from oxidation and the expression of MCP-1 is inhibited 
(Mackness et al., 2004). 
 
  
42 
 
2.4.1.3 Endothelial protection and antithrombotic activity 
Endothelium dysfunction or injury towards the endothelium caused by hypertension, 
diabetes, hypercholesterolemia and smoking is an early step for the development of 
atherosclerotic lesion. Studies have shown that low HDL-C is associated with endothelial 
dysfunction (Chan  et al., 2001), and high level of HDL-C are associated with improved 
endothelial dysfunction (Kuvin et al., 2002). 
 
The formation of endothelial dysfunction is characterized by decreased bioavailability of NO 
(nitric oxide) that is essential signaling molecules that induce relaxation in smooth muscle 
cells (SMC) (Yuhanna et al., 2001). Several in-vivo studies have supported this theory of 
effects of HDL on endothelial function comparing with hypercholaemia patient and non 
hypercholesterolemia suggesting that patient with hypercholesterolemia appear to have 
reduce NO bioavailability and when they are subjected for infusion of cholesterol free 
reconstituted HDL, restoration of endothelial function has been observed (Spieker et al., 
2002). 
 
The vasodilatory effects of HDL in endothelial cells are mediated by ABCG-1 and also 
includes 7-oxysterols and cholesterol efflux of cholesterol which improves the development 
of actives eNOS (endothelial nitric oxide synthase) dimers and results in reduced ROS 
production (Terasaka et al., 2008). Decreased in cellular production of superoxide also results 
in inactivation of NO. This eventually makes the bioavailability of NO increased and 
vasodilation is improved in the presence of HDL. Due to this HDL is proven to reduce the 
NADPH oxidase activity and expression of its major subunits in endothelial cells (Van et al., 
2009). 
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HDL also appears to have antithrombotic activity as the increase production of NO and PGI2 
(prostacyclin) which both plays an essential role in inhibiting platelet aggregation (Hassall et 
al., 1983; Whittle et al., 1980). PGI2 is also produced by endothelium which acts synergically 
with NO to induce SMC relaxation (Sickle et al., 1986).  
 
Besides NO and PGI2, reduction in PAF production by endothelial cells also contributes to 
the anti-thrombotic effects of HDL (Sugatani et al, 1996). Decrease in PAF production are 
caused by transportation of PAF acylhydrolase and other enzymes such as LCAT and 
paraoxonase that would degrade PAF (Forte et al., 2002; Satoh et al., 1991).  
 
Another point that would contribute to the antithrombotic activity of HDL is the level of 
HDL-C are inversely correlated with plasma concentration of VM Willebrand factor; a 
protein that is important in platelet adhesion and aggregation (Calabresi et al.., 2003). 
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2.5 Characteristics of CETP 
2.5.1 CETP gene and its regulation 
 
The gene for human CETP consists of 25kb of genomic DNA and includes 16 exons 
(Agellon et al., 1990). This gene appear as a single copy of chromosome 16q12-16q21 (Lusis 
et al., 1987). Some of the animal model such as hamster and rabbit shared almost 80 to 96% 
of amino acid sequence and overall sequence homology that similar to human CETP 
sequence homology (Drayna et al., 1987; Jiang et al., 1991; Nagashima et al.,  1988). That is 
why rabbit and hamster are commonly being used in CETP research as the subject of in-vivo 
study.  
 
Genetic variation of CETP also being observed in individual as a major determinant to 
identify individual that is prone to hyperlipidemia and coronary heart disease (CHD) (de-
Grooth et al., 2004). Some studies have recorded the effects of CETP polymorphisms on lipid 
profiles and CETP activity. Based on Ordovas et al. (2000), Taq 1B polymorphism at the 
CETP gene locus correlates to the changes in lipoprotein size, CETP activity, and HDL-C 
level. 
 
Based on Tall (1993), regulation of CETP gene expression are based on these factors; 
hormonal, inflammatory and nutritional stimuli. Several sites of the CETP mRNA 
expressions are liver, kidney, small intestines, spleen, adrenal and adipose tissue (Masucci-
Magoulas et al., 1995). The presence of CETP gene in adipose tissue shown that it 
contributes to the CETP activity which causes further reduction of HDL level and an increase 
in non-HDL-c levels (Zhou et al., 2006). 
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In response to high cholesterol diet, it causing up-regulation of CETP mRNA levels and 
increase in CETP plasma activity (Jiang et al., 1991). Regulation of CETP promoter activity 
involves SREBP and LXRS where SREBP1a and SREBP-2 stimulate CETP promoter 
through the interaction of CRE (cholesterol response element), while LXRα/RXRα and 
LXRβ/RXRβ will activate CETP promoter using DR4 element in a sterol-responsive fashion 
(Gauthier  et al., 1999). 
 
 
  
46 
 
2.5.2 Molecular structure of CETP protein 
The human CETP contain 476 amino acid residue hydrophobic glycoprotein and its 
translated mass are about ~ 53kDa, but the mass estimated by SDS-PAGE is 75 kDa (Drayna 
et al., 1987). The cause of the discrepancy between translated molecular mass and SDS-
PAGE is due to the N-glycosylation sites at residues 88, 240, 341 and 396 (Tall, 1993). 
 
The crystal structure of CETP was solved in 2007 by using X-Ray crystallography (Qiu et al., 
2007) PDB id: 20BD. Based on this model, the shape of CETP protein has been described as 
a boomerang with dimension 135Å X 30Å X 35Å. The overall structure is divided by 4 units: 
1) Two terminal at each end of the protein (N- and C- terminal) 
2) A central β-sheet that acts as a linker that connects the two terminal and includes six 
antiparallel strands consist of residues before and after terminal 
3) Each terminal contains a highly twisted β-sheet and two helices. Helices are denoted 
as A and B at N-terminal and A’ and B’ at C-terminal. 
4) Distorted amphipathic helix which is called as helix X that is formed by amino acid 
GLU465 – SER476 at the C-terminal domain.
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Figure 19 Crystal structure of CETP using ribbon diagram. Two domains in the structure which are N-terminal (green) and C-terminal 
(yellow) with linker that is shown in red colour. CE1(magenta) and CE2(cyan) are shown in the middle space of the structure and 
phospholipids are being labeled as black bonds. Helices A, B, A’ ,B’ and X are labeled. Helix X belongs to the C-terminal domain but 
interacts with residues of the N-terminal domain. (Qiu et al., 2007)
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Based on this CETP structure models, revealed that, there are four bound lipid molecules 
which is being incorporated during protein production. CETP has the 60 Å length of tunnel 
that contains CE and phospholipid at each of the terminal. 
 
The concave surface of CETP which is consists of N and C terminal openings, helix X and 
Ω1 flap is the most probable site for lipoprotein binding (Qiu et al., 2007). It is hypothesized 
concept that lipoproteins are likely to be binding at concaved structure compare to other 
CETP surfaces which are highly glycosylated and do not have proper curvatures to properly 
binds spherical lipoprotein and does not provide proper access to the tunnel opening. 
 
A biochemical study was done by Bruce et al. (1995) demonstrated that CETP has a higher 
binding affinity towards 10nm diameter nascent discoidal HDL, and this diameter does 
correspond to the diameter of the concave surface of CETP. The author (Qiu et al., 2007), 
hypothesizes that prior binding of HDL towards CETP surfaces may cause the insertion of 
Helix X into the bound lipoprotein where this concept is consistent with the role of helix X 
that facilitates the access of neutral lipid from lipoprotein to CETP tunnel. 
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2.5.3 Function of CETP 
 
CETP is known as the protein that is responsible for the transfer of water insoluble lipids 
such as CE, TG, and phospholipids to VLDL and LDL (Qiu et al., 2007). Two different 
mechanisms of lipid transfers have been proposed (Morton & Greene, 2003). 
 
The first mechanism which is called as ‘shuttle’ or ‘ping-pong’ mechanism has been 
consistent with the X-ray crystallography structure that has been resolved by Qiu et al. 
(2007), which shows that overall boomerang shape with a concave surface can bind only one 
lipoprotein at one time. This structure supports the hypothesis saying that CETP acts as a 
carrier mechanism. Neutral lipids are accepted by CETP from donor particle to the 
hydrophobic tunnels. This will then be transported to the aqueous phase and finally being 
delivered to the lipoprotein acceptor (Tall, 1993).     
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Figure 20 Basic schematic diagram of CETP function. Middle, CETP in plasma is being 
describes by its concave surfaces. Top, CETP binds to Triglyceride-rich lipoprotein and 
will cause triglycerides to be extracted into CETP hydrophobic tunnel and phospholipid 
will be introduced to protein surfaces. Bottom, CETP binds to HDL and extracting 
cholesteryl ester from lipoprotein monolayer into the hydrophobic tunnel and 
introduced phospholipid to protein surfaces. This model showed that CETP can 
accommodate different sized of spherical lipoprotein and its concave structure by 
changing its own curvature.(Hamilton & Deckelbaum, 2007) 
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This carrier mechanism can occur via homoexchange or heteroexchange (Ko  et al., 1994; 
Morton & Zilversmit, 1983; Serdyuk & Morton, 1999).  Homoexchange occurs when there is 
a bidirectional transfer of the same kind of neutral lipids that is bound, being loaded into the 
tunnel which results in no net exchange of lipoprotein lipid content (Qiu et al., 2007).  
 
Heteroexchange mechanisms is part of RCT mechanism and because of this CETP does plays 
a crucial role in lipoprotein mechanism (Asztalos et al., 2004). The proposed mechanism of 
CETP-mediated heteroexchange are as follows:  
 
Step 1: CETP that contains CE will bind into VLDL and releases bound phospholipid 
(phosphatidylcoline). One or two TG enters the tunnel, and equal amount of CE is transferred 
into VLDL to create balance. 
Step 2: TG bound CETP is then disattached or dissociates from VLDL. This leaves the 
VLDL particles with a higher CE content. 
Step 3: The bound CETP binds to HDL and releases the phosphatidylcholine. One or two TG 
will enters the tunnel and to create balance, TG is transferred into HDL. 
Step 4: The CE-filled CETP dissociates from HDL and this completes the heteroexchange 
which results in lower CE content in HDL. 
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Figure 21 Proposed mechanism of CETP-mediated heteroexchange. 1) CETP filled with 
CE binds to VLDL and releases bound phospholipid which also known as 
phosphatidylcholine, PC. One or two TG enters the hydrophobic tunnel and equal 
amount of CE is located into VLDL. 2) The TG-bound CETP disengaged from VLDL 
carrying two phospholipids from the surface, leaving VLDL with higher CE content. 
3)The TG bound CETP employs HDL and disengaged the bound phospholipids One or 
two new CEs enter the tunnel and an equal amount of TG is deposited into HDL.4) The 
CE filled CETP dissociates from HDL carrying two phospholipids from the surface and 
accomplish full cycle of heteroexchange which results in lower CE content in HDL.  (Qiu 
et al., 2007) 
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The depletion of CE in HDL is particularly influenced by TG level (Davidson & Rosenson, 
2009). Due to this heteroexchange , RCT routes are mainly through VLDL and LDL and will 
further taken up to the liver via SR-B1. However, in abnormal at which CETP activity are 
increased due to the increased of CETP gene expression in peripheral and increase the 
concentration of lipoprotein acceptor (Tall, 1993). This may cause an increase in the transfer 
rate of CE to LDL and VLDL, which may cause accumulation in the intima. 
 
In the deficiency of CETP, all the neutral lipid transfer are absent. This means that, in HDL 
particle the TGs level are reduced, and CE content is increased. Due to the deficiency of 
CETP and continued activity of LCAT, the size of HDL particles gradually increases and 
acquire lipoprotein E. This condition provides high-affinity ligand for LDL receptor of the 
liver, thus removing the increase HDL particles and cholesterol from the tissues (Tall, 1993). 
Deficient or absent of CETP cause HDL build up and this eventually reduced the amount of 
cholesterol transfer to LDL and VLDL (Clark et al., 2006). The theory of CETP deficiency 
correlates with reduced risk of atherosclerosis. This cause great interest in CETP inhibition as 
the alternatives to increase HDL-c levels. 
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2.5.4 The development of CETP inhibitors and its current update 
 
The pathway to inhibit CETP has emerged as an attractive target to elevate HDL-C level as a 
strategy to reduce the risk of cardiovascular event. In the classic way of understanding the 
drug inhibition, the analogy that usually being used is that a lock and a key. Drugs act as a 
competitive inhibitor at which it binds to the active sites, thus blocking the binding of the 
ligand. 
 
However, in the case of CETP inhibition mechanism, it has been demonstrated that the 
inhibitors promote CETP-HDL complex formation, which indicates the current inhibitor 
prevent detachment of CETP-HDL complex and they do not compete with CE and TG in the 
CETP binding (Masson, 2009). As of these various inhibitory mechanism, further elucidation 
needs to be done. Understanding the molecular structure and function of CETP together with 
the inhibitors mechanism of action are important to develop a safe treatment to raise HDL-C 
treatment. 
 
2.5.4.1 Failed CETP inhibitors: torcetrapib and dalcetrapib 
 
Torcetrapib or also known previously as CP-529414 is a noncompetitive inhibitor  and its 
bind reversible to CETP to form an inactive CETP-HDL complex (Clark et al., 2006; 
Ranalletta et al., 2010). Torcetrapib has nearly entering phase 3 clinical trials but during the 
phase 2 studies, torcetrapib has cause elevated blood pressure among the tested patient. The 
failure of torcetrapib is due to is failure to achieve clinical benefit plus the administration of 
torcetrapib also causing harm. Due to this, in December 2006, torcetrapib phase 3 
ILLUMINATE clinical trial was terminated. This termination is because of the significantly 
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increase the risk of primary combined endpoint of death from coronary heart disease, stroke, 
myocardial infarction or hospitalization of instable angina (Barter, 2009) that associated with 
torcetrapib administration although there are significantly increase in HDL and reduce in 
LDL. 
                                  
Figure 22 Chemical structure of Torcetrapib 
 
The off target outcomes from the administration of torcetrapib are increase in the aldosterone 
production (Barter et al., 2007) and increase in high blood pressure.  
 
Several in-vitro studies confirmed the upregulation of CYP11B2 (aldosterone synthase) with 
torcetrapib administration (Forrest et al., 2008; Funder, 2010; Hu et al., 2009).  Theoretically, 
an excess level of aldosterone promotes sodium retention at the distal renal tubule which 
results in water retention and an increase in blood pressure (Funder, 2010). Patients that are 
being diagnosed as hyperaldosteronism shows an increase risk of associated cardiovascular 
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events such as myocardial infarction, stroke, heart failure, left ventricular hypertrophy and 
atrial fibrillation (Connell  et al., 2008; Milliez et al., 2005). 
Dalcetrapib or also known as RO4607381 / JTT-705 is one of the CETP inhibitors that 
undergoes clinical trial phase III. Dalcetrapib is a less potent inhibitor with its IC50 >1000nm 
(Ranalletta et al., 2010). Dalcetrapib phase III trial was terminated since it failed to show 
meaningful or significant clinical outcome although there are no off-target being observed 
although HDL-C were elevated by 30% (Schwartz et al., 2009). 
 
                           
Figure 23 Chemical structure of Dalcetrapib 
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2.5.4.2 Ongoing Phase 3 clinical trial of CETP inhibitors: Anacetrapib and evacetrapib 
 
Anacetrapib or MK-0859 has the almost similar IC50 with torcetrapib (IC50:21nM) which 
also results in the increase of HDL and reduce the atherogenic lipoprotein (Bloomfield et al., 
2009). The highly potent CETP inhibitor is evacetrapib (LY2482585) with IC50 5nM has just 
entered phase 3 clinical trial (Cao et al., 2011). 
                                    
Figure 24 Chemical structure of anacetrapib 
 
Unlike torcetrapib, anacetrapib and evacetrapib did not exacerbate any off target outcomes. 
Both of these inhibitors exhibited a neutral level of blood pressure, neutral level of 
aldosterone synthesis and it does increase HDL-C. Due to the failures of torcetrapib and 
dalcetrapib, both anacetrapib and evacetrapib are still under investigation to evaluate any 
possible side effects. The ongoing REVEAL (Randomized Evaluation of the effects of 
anacetrapib through lipid modification) trial of anacetrapib is studying the possible outcomes 
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where 30 000 patients with atherothrombotic cardiovascular disease will be randomized to 
anacetrapib or placebo administration and will be followed for 4 to 5 years. This study will 
evaluate the outcomes such as coronary death, myocardial infarction or coronary 
revascularization (University of Oxford, 2012). 
 
Evacetrapib also just recently entering phase 3 clinical trial in the ACCELERATE (A study 
of Evacetrapib in High Risk Vascular Disease) where approximately 11000 patients were 
appointed in a randomized placebo-controlled study of evacetrapib. This study is estimated to 
complete in 2015 where several possible outcomes are being evaluated such as 
cardiovascular death, stroke, myocardial infarction, coronary revascularization or 
hospitalization for unstable angina (Eli Lilly and Company, 2012). 
                                   
Figure 25 Chemical structure of evacetrapib 
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2.6 Selection of Garcinia atroviridis 
 
Garcinia atroviridis Griff ex T anders of the Guttiferae family are also known as ‘ asam 
gelugor’ or ‘asam keping’ among Malaysian. It is a medium-sized fruit tree that grows wild 
throughout Peninsula Malaysia and are also being cultivated commercially in northern of 
Malaysia due to it’s economic and medicinal value (Burkill et al., 1966).  
 
Garcinia atroviridis is a tree that can grow up to 20m and it has orange-yellow depressed 
globosed fruit with 7 to 10cm diameter. The fruit is usually being sun dried for consumption 
which is later being called as ‘asam keping’ and are usually being used for seasoning 
purposes such as dressing fish, curries and sour relish (Mackeen et al., 2002). 
 
The young leaves are usually being used as “ulam” which is later being cooked or consumed 
raw as a salad (Mackeen et al., 2000). Some of the Malay recipe uses Garcinia atroviridis in 
steam fish in order to delay early spoilage. Garcinia atroviridis also being used as postpartum 
medication agent, treating ear and throat infection, cough, dandruff and some stomach-ached 
during pregnancy (Amran  et al., 2009). Some of the post-partum medication that is being 
used is making juice from the leaves for women during confinement and lotion that is made 
from the fruit and vinegar, and this lotion will be applied upon abdomen of women during 
confinement (Amran  et al., 2009). 
 
Several phytochemical studies have successfully isolate some of the compounds from 
Garcinia atroviridis such as garcinia acid and its lactone from fruit rinds, flavonoids, 4-
methylhydroatrovirinone, atrovirinone, atrovirisidone in roots and atroviridine from stem 
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bark (Kosin et al., 1998; Mackeen et al., 2002; Permana et al., 2001; Dharma et al., 2005; 
Tan et al., 2013). 
 
Garcinia atroviridis also demonstrates a wide range of pharmacological effects such as anti-
inflammatory, antiplatelet, antioxidant, antithrombotic action and anti-allergic effects 
(Mackeen et al., 2000). Some studies also successfully reduce blood pressure in rats by using 
Garcinia atroviridis extracts (Amran et al., 2009). 
 
From the beginning of human civilization, medicinal plant natural product have been used 
due to its therapeutic value. It undergoes design, synthesis, semi-synthesis to create potent 
medicinal agents. The search for biologically active constituents which is from natural 
product based on traditional use or folklore medicine is still relevant as these plants have the 
potential to produce pharmacologically active constituent to treat certain diseases.  
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Chapter 3: Experimental methods 
3.1 Sample preparation 
3.1.1 Plant Collection  
The leaves of Garcinia parvifolia were collected from the lowland dipterocarp, Sungai 
Congkak Reserve Forest in Malaysia. The forest is located at 3º 12.930’N, 101º 53.022’E 
with the altitude ranging from 120m – 1265m above the sea level (Ng & Mariam, 2009) . A 
voucher specimen (UNMC45L) was deposited at the Herbarium of The University of 
Nottingham, Malaysia Campus. L are denoted as leaves. 
 
The Leaves (L), twigs (T) and fruit (F) of Garcinia atroviridis were obtained from Bukit 
Ekspo, Universiti Putra Malaysia, Serdang around November 2011 and the voucher specimen 
named as UNMC78L, UNMC78T and UNMC78F were deposited at The University of 
Nottingham Malaysia campus.   
3.1.2 Plant extraction 
The plant material for UNMC 45L, UNMC 78L, UNMC 78T and UNMC 78F were dried at 
the atmospheric temperature (~30 ˚C) and shaded from sunlight for 1 month.  
 
The dried plant were pulverised into smaller parts and subjected to maceration for over 3 
days by using sequential gradient extraction of different polarity of solvents starting with 
hexane, ethyl acetate and ethanol. Solvents were removed after 3 days of maceration by using 
distillation under reduced pressure at 40˚C and later the crude extracts were pooled together 
for every and each specific solvent and this procedure were repeated for three times. All the 
extracts were dried in desiccators until it is concentrated. The residues obtained were 
designated as aqueous extracts and stored at -20˚C until assayed. 
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3.2 CETP drug screening assay 
3.2.1 Sample preparation 
Extracts The extracts were prepared by dissolving in DMSO solvent in order to make stock 
solutions .The stock solutions were subjected to vortex and sonication when there was 
difficulty in dissolving. Subsequent serial dilutions were made to the required concentrations 
using distilled deionized water. The final concentration of DMSO was adjusted to 0.1%. 
 
Chemical The analytical standard (+)- Garcinia acid was purchased from sigma Aldrich and 
it was further being diluted with DMSO until the final concentration of 1% DMSO. 
                                              
Figure 26 Structure of Garcinia acid 
 
3.2.2 Principle of the inhibitory assay 
The CETP inhibitor drug screening kit (BioVision, Mountain View, CA, USA) uses donor 
molecule containing a fluorescent self-quenched neutral lipid, which is transferred to an 
acceptor molecule in the presence of the CETP (rabbit serum). The lipid transfers of donor 
molecule to the acceptor molecule mediated by CETP will results in an increase of 
fluorescent intensity. Whereas, in the present of the inhibitor will hinder the lipid transfer and 
therefore will cause the decrease in fluorescent intensity.   
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3.2.3 Determination of CETP inhibitory activity 
To assess the percentage inhibition of the crude extracts towards CETP, fluorescence 
bioassay was carried out by using the CETP Drug Screening Kit (#k602-100, BioVision, 
Mountain View, CA, USA). The procedures of the assay can be described briefly as follows: 
50 μl of the inhibitors were added, followed by 3 μl of rabbit serum. Then the master mix 
which is being provided in the assay kit (10 μl of Donor Molecule, 10 μl of Acceptor 
Molecule and 20 μl of CETP buffer) was added, mixed well and the volume was completed 
to 203 μl with the provided assay buffer. The mixture was subjected to incubation for 1 hour 
at 37°C, and the fluorescence intensity was measured by using fluorescence plate reader 
(Varioscan Flash, ThermoScientific) at Excitation wavelength of 465 nm and Emission 
wavelength at 535 nm. The percentage inhibition of the extracts towards CETP was 
determined by comparing the activity of CETP in the presence and absence of the tested 
compound. As a background, negative control lacking of rabbit serum was being used. 
Positive controls were tested in order to see the degree of inhibition by 0.1% DMSO, and 
CETP was not being affected by DMSO. All the measurements were carried out in triplicate. 
The percentage inhibition of the extracts towards CETP activity was calculated as follows: 
 
Percentage Inhibition 
= (1 − [
sample read − blank read
Positive control read − Negative control read
]) x 100 
3.3 Enzyme kinetic assay 
Same procedure as 3.2.3 except that the readings were collected for 60 minutes at every 1 
minutes interval.  
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3.4  Phytochemical screening 
Several tests were performed to confirm the presence of secondary metabolites: alkaloid, 
flavonoid, saponin, tannin, steroid, terpenoid and phytosterol.  
 
Phytochemical analysis of plant extracts for active compound was carried on according to 
Igbinosa et al., 2009; Savithramma & Rao, 2011; Tiwari et al., 2011. All of the test were 
carried out in triplicate. 
 
3.4.1 Detection of alkaloids  
0.5g of the extracts were dissolved individually in 10ml of dilute Hydrochloric acid and 
filtered. Two tests (Wagner’s Test and Dragendroff’s Test) were performed in order to 
confirm the presence of alkaloids in the extracts.  
 
3.4.1.1 Wagner’s Test  
2ml of the filtrates were treated with Wagner’s reagent (Iodine in Potassium Iodide). 
Formation of brown/ reddish precipitate indicates the presence of alkaloids. 
 
3.4.1.2 Dragendroff’s Test  
2ml of the filtrates were treated with Dragendroff’s reagent (solution of Potassium Bismuth 
Iodide). Formation of red precipitate indicates the presence of alkaloids.  
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3.4.2 Detection of flavonoids 
0.5g of the extracts were subjected to two types of flavonoids testing which are (Alkaline 
reagent test and Lead acetate test) in order to confirm the presence of flavonoids in the 
extracts. 
 
3.4.2.1 Alkaline Reagent Test  
0.5g of the extracts were treated with few drops of 0.5M sodium hydroxide solution. 
Formation of intense yellow colour, which becomes colourless on addition of 1ml of dilute 
sulphuric acid, indicates the presence of flavonoids.  
 
3.4.2.2 Lead acetate Test  
0.5g of the extracts were treated with few drops of lead acetate solution. Formation of yellow 
colour precipitate indicates the presence of flavonoids. 
 
3.4.3 Detection of saponins 
0.5g of the extracts were subjected to two types of saponin testing which are (Froth test and 
Foam Test) in order to confirm the presence of saponins in the extracts. 
 
3.4.3.1 Froth test  
0.5g of the extracts were diluted with distilled water to 20 ml and this was shaken in a 
graduated cylinder for 15 minutes. Formation of 1 cm layer of foam indicates the presence of 
saponins. 
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3.4.3.2 Foam test  
0.5g of the extracts was shaken with 2 ml of water. If foam produced persists for 10 minutes 
it indicates the presence of saponins. 
 
3.4.4 Detection of tannins (Gelatin Test) 
0.5g of the extracts were added to 1% gelatin solution which contains sodium chloride. 
Formation of white precipitate indicates the presences of tannins. 
 
3.4.5 Detection of steroid/ terpenoid (Salkowski’s Test) 
0.5g of the extracts were treated with chloroform and filtered. 2ml of the filtrates were treated 
with few drops of concentrated Sulphuric Acid, shaken and allowed to stand. The appearance 
of golden yellow colour indicates the presence of terpenoid. The presence of blue or green 
interface corresponds to the presence of steroid. 
 
3.4.6 Detection of phytosterols (Libermann Buchard’s Test) 
0.5g of the extracts were treated with chloroform and filtered. The filtrates were treated with 
few drops of acetic anhydride, boiled for 15 minutes and cooled. 1ml of concentrated 
sulphuric acid was added. Formation of brown ring at the junction indicates the presence of 
phytosterols. 
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3.5 Statistical Analysis:  
The results of three independent experiments were obtained and the values were presented as 
mean ± standard deviation (SD). One-way analysis of variance (ANOVA) test were applied 
to analyse P value. P-values less than 0.05 were considered as statistically significant. All 
statistical analyses were performed by using GraphPad Prism 5.0 (GraphPad Software Inc., 
San Diego, CA). 
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3.6 Verification of HCA content in crude extract of UNMC 78F 
3.6.1 Verification using FTIR spectrophotometry method 
The FTIR spectra from ethanol extracts were generated by 100 FTIR PelkinElmer (USA). 
Prior to the sample loading, the stage was cleaned and blanked. A drop of concentrated crude 
extract was placed on the reading spot and scanned. The absorbance peaks were produced 
with a resolution of 4 m-1   (4000–500 cm-1) and averaged 32 scans. The spectra were 
analyzed by baseline correction and attenuated total reflectance (ATR) to directly investigate 
the chemical composition of smooth surfaces and undisturbed state of various materials in the 
sample (Schmitt and Flemming, 1996). Each samples were triplicated and the best results 
selected for functional groups verification.  
 
3.6.2 Verification using HPLC method 
(-) Garcinia Acid (C6H6O7) from Sigma Aldrich were taken as reference standard. The high-
performance liquid chromatography system used in this study was from Agilent (1260 
Infinity Series, 1260 Quad Pump) with C18 RP column 4.6 x 150 mm. The system consists of 
Rheodyne injector with sample loop of 20 µL, OpenLab CDS (Chem station edition) 
software. In the present study, attempts were made based on HPLC methodology from the 
existing protocol (Gogoi et al., 2014). 
 
The mobile phase used was HPLC grade (Millipore) water and the HPLC method was carried 
out taking a series of different (-)- HCA concentrations with final preeminent flow rate of 1.0 
ml/min. Detection was done by Dual λ absorbance detector at a wavelength of 210 nm and 
sample eluted was 20 µL for 8 minutes at 58/8 bar Quart pump and 25 º C of column 
temperature. Prior to injection to the HPLC system, all the samples and the standards were 
filtered through membrane filters of pore size 0.45 µm. As water has been used in this study, 
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to maintain the efficiency and column life after completion of the experiment it is purged 
several times with methanol. 
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3.7 Molecular docking using GLIDE 
3.7.1 Overview of docking methodology  
 The docking methodology that was being used in this project is based on GLIDE (grid-based 
ligand docking with energetics) that was being implemented together with Schrodinger suite. 
GLIDE uses a hierarchical filter to search the best position with the active site of the protein. 
The GLIDE algorithm is based on the systematic search of conformations, positions, 
orientations of a ligand in the protein active site using the funnel type approach (Friesner et 
al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 GLIDE docking hierarchy using the 'funnel' theory (Friesner et al., 2004) 
 
The docking scoring were carried out using GLIDE Score function where GLIDE energy was 
being used to predict binding affinity.  
 
Ligand Conformation 
2b. Subset test 
2a. Diameter test 
3. Grid minimization +  
Monte carlo 
2c. Greedy score 
2d. refinement 
1. Site-point search 
4. Final scoring (GLIDE score) 
Top hits 
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Small numbers of best-refined poses were passed on the following stage in the hierarchical 
energy minimization on OPLS-AA van der waals and electrostatic grids for the protein. The 
best poses were chosen and subjected to Monte Carlo simulations and it will be rescored 
using GlideScore function.  
 
GLIDEscore can be defined below: 
GScore = 0.065 * vdW + 0.120 * Coul + Lipo + HB + Metal +BuryP + RotB + Site 
 
Where, 
vdW = van der Waals energies 
Coul = represents Coulomb energy 
Lipo = hydrophobic term 
HB = hydrogen bonding term 
Metal = anionic interactions with metal cations 
BuryP = buried polar group 
RotB = frozen rotable bond 
Site = polar but non hydrogen bonding atoms that exist in hydrophobic region 
 
3.7.2 Ligand structure preparation 
All the compounds were constructed using 2D-sketcher using the Schrodinger graphical user 
interface Maestro 8.5.  The illustration in 2D-sketcher can be converted into 3D structure 
when it is being exported into the workspace (Friesner et al., 2004). 
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3.7.3 Protein structure preparation 
A typical PDB protein complex structure can be downloaded from the Research Collaborator 
from the Research Collaborator for Structural Bioinformatic (RCSB) website 
(http://www.rcsb.org). The PDB identification (PDB ID) for CETP are 2OBD (native 
protein) and 2EWS (torcetrapib attached). The PDB structures for CETP were corrected 
using protein preparation wizard that can be found in Maestro. The structures were prepared 
for docking with the protein preparation wizard using the following default steps: assigning 
bond orders, adding hydrogens, treating metals, creating disulfide bonds, converting 
selenomethionines, deleting waters, assigning H-bond network, structure minimization in 
vacuum up to 0.3 Å RMSD by using OPLS_2005 force field. After preprocessing and 
preparation steps, the H-bonds were further optimized. All waters molecules and additional 
ligands were deleted from the structure.  
 
3.7.4 Receptor Grid Generation 
Ligand docking jobs cannot be performed until grids are fully generated. The set up of grid 
generation can be done from the Receptor Grid Generation drop-down menu from maestro. 
The grid size can be determined from the position and the size of the active site.  The 
maximum available grid size was 36 x 36 x 36 Å3 outer box and 14 x 14 x 14 Å3 inner box. 
The force field that is being used for grid generation was OPLS_2005 force field.  
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Figure 28 The image of 2OBD protein in ribbon diagram format. The purple colour box 
indicates the grid box that was being generated before the docking procedure begun.  
 
3.7.5 Docking protocol   
Molecular docking using Glide that was being developed by Schrodinger (Glide,2014) was 
performed to investigate the binding mode between the active site of CETP and prepared 
ligands. The docking ligands were treated flexibly, and the prepared protein was held rigidly 
during the docking procedure. The conformations are further refined via Monte Carlo 
sampling of pose conformations. There were 20 poses being collected.  
 
3.7.6 Confirmation of docking using GOLD suites 
In order to validate the docking poses, GOLD suites were being employed to dock the ligands 
of interest with CETP (PDB ID: 2OBD).  GOLD uses a Genetic algorithm for searching 
binding space and ligand conformational space and it employs matching of pharmacophore 
points to generate ligand poses (Verdonk et al., 2003). GOLD uses several scoring functions, 
which includes GoldScore, ChemScore, ASP and ChemPLP.  
 
The protein and ligands were first being prepared in Maestro interface and the ligands were 
docked into the active sites using GOLD suites. Binding site of CETP was defined as all the 
residues that are located within 10Å from CE atom in N terminal. The default parameters if 
GOLD suites was using genetic algorithm (GA) in order to search for the reasonable 
conformation of ligands. The maximum number of GA runs was set to 10. The total number 
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of poses available was 10. Based on the three scoring function, chemscore fitness function 
has been chosen in order to evaluate the docking conformation (Guo et al.,  2004) 
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3.8 Molecular Dynamic Study using Desmond 
3.8.1 Overview of Molecular Dynamic methodology 
Molecular dynamic (MD) simulations is best to describe molecular motions of a system 
based on time and space using applied force fields. This technique gives virtual 
understandings into the atomic fluctuations but it is mainly based on the applied force fields, 
electrostatic interactions and motion assimilation through distinct time frame. 
 
Three basic stages for MD simulation contains:  
1) setup  
2) equilibrium 
3) run. 
 
In the setup stage, the protein were inserted with water, soaking the protein into the 
membrane and also soaking the protein-membrane complex into a box of water. The system 
underwent energy minimization and heated gradually to the desired temperature for 
simulation and later will be equilibrated. In the equilibration stage, the protein heavy atoms 
were restrained and it will slowly released until the full system was stable and unrestrained. 
The MD simulation was based on force field method and it was basically obey Newton’s 
second law: 
 
F = ma 
F = net force of an object 
m = mass of an object 
a = acceleration of an object 
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3.8.2 Molecular Dynamic Simulation protocol 
The docking results from GLIDE were subjected to long equilibrium molecular dynamic 
(MD) simulations by using Desmond (Schrödinger Release 2015-1, 2015) with default 
OPLS_2005 force field.  
 
The ligand-protein complex was embedded in POPC(1-palmitoyl-2-oleoyl-sn-glycer-3-
phosphocholine) membrane and solvated with TIP3P water in a periodic orthorhombic box 
with 10 Å x 10 Å x 10 Å distance through the Desmond system builder which can be found 
in Maestro interface. In order to maintain the neutrality of the system, sodium and chloride 
ions were added. 150 mM Na+Cl- were added as well in order to simulate the physiological 
condition of the system.  The final system consisted of 69370 atom. 
 
The system undergoes energy minimization using the Desmond minimizer which can be 
found in Maestro interface, which uses limited-memory-Broyden-Fletcher-Goldfard-Shanno 
(LBFGS) and steepest decent algorithms.  Simulations were conducted with a constant 
temperature of 300 K using Nosé-Hoover chain thermostat (Martyna et al., 1992) and 
Martyna-Tobias-Klein barostat methods Martyna et al., 1994). The simulations were run for 
10s and 20ns in total. Long-range electrostatic interaction was calculated using particle mesh 
Ewald algorithm (Darden et al., 1999). The systems were undergoing default relaxation 
protocol before the MD simulation.  
 
The system undergoes eight steps MD simulation protocol that involves: 
 
Stage 1: Task 
Stage 2: Simulate 
Stage 3: Simulate, Berendsen NVT, T=10 K, Small timesteps, and restraints on heavy solute 
atoms 
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Stage 4: Simulate, Berendsen NPT, T=10 K, and restraints on heavy solute atoms 
Stage 5: solvate_pocket 
Stage 6: simulate, Berendsen NPT and restraints on heavy solute atoms 
Stage 7: simulate, Berendsen NPT and no restraints 
Stage 8: simulate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
Trajectories were further analysed using desmonds. All the simulations were evaluated based 
on system potential energies, calculation of the radius gyration, root mean square (RMSD) 
and root mean square fluctuation of the protein (RMSF). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29 Flowchart of MD simulation by Desmond 
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3.9 Virtual Screening and SAR (Structural Activity Relationship) studies of 
HCA analogues against CETP 
 
3.9.1 Preparation of the compound libraries 
An analogue is described as a structure that is related to the drug of interest, in which 
biological and chemical properties might differ. As part of structure-activity relationship 
study, structural analogs of an initial lead compound are tested. The analogs were retrieved 
from web-accessible ZINC three-dimensional (3D) (www.zinc-docking.com). Zinc 3D is a 
database that compiles chemical structures, and it contains 13 million of compound (Irwin & 
Shoichet, 2005; Irwin et al., 2012). 
 
The compound library that is obtained from ZINC 3D database is further processed with 
Ligprep module in Maestro interface. A set of 9 ligands were prepared using Ligprep module. 
 
3.9.2 Preparation of protein binding sites and targets 
The three dimensional structures of CETP are obtained through RCSB website with the PDB 
ID:2OBD. The PDB structures for CETP were corrected using protein preparation wizard 
that can be found in Maestro. The structures were prepared for docking with the protein 
preparation wizard using the following default steps: assigning bond orders, adding 
hydrogens, treating metals, creating disulfide bonds, converting selenomethionines, deleting 
waters, assigning H-bond network, structure minimization in vacuum up to 0.3 Å RMSD by 
using OPLS_2005 force field. After preprocessing and preparation steps, the H-bonds were 
further optimized. All waters molecules and additional ligands were deleted from the 
structure. The set up of grid generation can be done from the Receptor Grid Generation drop-
down menu from maestro by using OPLS_2005 force field. 
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3.9.3 Docking simulations and ligands ranking 
All analogue compounds that were prepared earlier were docked into the binding site using 
Glide. The Glide SP was employed here to screen all the analogues and a maximum number 
of poses per ligand was set 100 before it being passed to grid-refinement calculation. One 
good conformation for each molecule which being ranked by Emodel score where Emodel 
combines GLIDEScore with non-bonded interaction energy with the internal energy of the 
generated ligand conformation. All molecules with the highest ranking poses (G-score) were 
selected for further experimental analysis. 
 
3.9.4 CETP assay for the analogs  
Chemicals: DL-isocitric acid trisodium salt hydrate, and potassium hydroxycitrate tribasic 
monohydrate were purchased from Sigma Aldrich, and it was being diluted with 1% DMSO.  
 
In order to assess the percentage inhibition of the analogs towards CETP, a fluorescence 
bioassay was carried out by using the CETP Drug Screening Kit (#k602-100, BioVision, 
Mountain View, CA, USA). The procedures of the assay can be described briefly as follows: 
50 μl of the inhibitors were added, followed by 3 μl of rabbit serum. Then the master mix 
which is being provided in the assay kit (10 μl of Donor Molecule, 10 μl of Acceptor 
Molecule and 20 μl of CETP buffer) was added, mixed well and the volume was completed 
to 203 μl with the provided assay buffer. The mixture was subjected to incubation for 1 hour 
at 37 °C, and the fluorescence intensity were measured by using fluorescence plate reader 
(Varioscan Flash, ThermoScientific) at Excitation wavelength of 465 nm and Emission 
wavelength at 535 nm. The percentage inhibition of the extracts towards CETP was 
determined by comparing the activity of CETP in the presence and absence of the tested 
compound. As a background, negative control lacking rabbit serum was being used. Positive 
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controls were tested in order to see the degree of inhibition by 0.1% DMSO and CETP were 
not affected by DMSO. All the measurements were carried out in triplicate. The percentage 
inhibition of the extracts towards CETP activity was calculated as follows: 
 
 
Percentage Inhibition 
= (1 − [
sample read − blank read
Positive control read − Negative control read
]) x 100 
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Chapter 4: Results and Discussion  
Secondary metabolites that is being isolated from natural product are often used as medicines 
(Sung  et al., 2004). Up to date, there are several research that has been done in order to 
identify plants that has the ability to reduce the plasma low lipoprotein level (Amran et al., 
2009; Khalili et al., 2009).   
 
Torcetrapib, is a potent inhibitors for CETP which shows assuring results towards inhibition 
of CETP activity, increases in HDL-c levels and affect reduced progression of atherosclerosis 
in animal models (Okamoto et al., 2000). However, during phase 2 of ILLUMINATE study, 
administration of torcetrapib has caused off target results which are increase in production of 
aldosterone and elevated blood pressure among tested patient. This considered as failure 
since it cause higher risk of combined end0point of death from coronary heart disease, stroke, 
myocardial infarction and hospitalization due to instable angina (Barter, 2009).  
 
This led to the increase interest of research towards other CETP inhibitors especially in 
natural product. Plants have well documented for their medicinal uses for thousands of years. 
They have evolved and adapted over millions of years to withstand bacteria, insects, fungi 
and weather to produce unique, structurally diverse secondary metabolites. Their 
ethnopharmacological properties have been used as a primary source of medicines for early 
drug discovery (Butler, 2004). According to World Health Organization (WHO), 80% of 
people still rely on plant-based traditional medicines for primary health care (Farnsworth  et 
al.,  1985) and 80% of 122 plant derived drugs were related to their original 
ethopharmacological purpose (Fabricant and Farnsworth, 2001). The knowledge associated 
with traditional medicine (complementary or alternative herbal products) has promoted 
further investigations of medicinal plants as potential medicines and has led to the isolation 
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of many natural products that have become well known pharmaceuticals. These explain that 
plant natural product provides a suitable platform as a candidate for CETP inhibitors. All of 
the plants that were being chosen for preliminary screening against CETP were chosen due to 
their ethnopharmacological properties that possess the cholesterol lowering properties.  Due 
to this interest, all of the plants which are UNMC78 and UNMC 45L were chosen and to be 
tested their potency against CETP activity. Up to date there is no specific protocol that has 
been developed in search of CETP inhibitors from plant natural products especially that 
contains crude extracts which is known to possess many secondary metabolites.  
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4.1 Plant collection and identification 
Garcinia atroviridis Griffith ex T. Anderson plant parts (leaves, twigs and fruits) were 
collected from Taman Botani, Universiti Putra Malaysia and was identified by botanist in 
Universiti Putra Malaysia.  Garcinia atroviridis was deposited in University of Nottingham 
Malaysia Campus herbarium as UNMC 78 where UNMC 78L was indicated as leaves of 
Garcinia atroviridis, UNMC 78T as twigs of Garcinia atroviridis and UNMC 78F as fruit of 
Garcinia atroviridis.  
 
Figure 30 Garcinia atroviridis plant found in Taman Botani, UPM.  
85 
 
 
Figure 31 Young leaves of Garcinia atroviridis 
 
 
 
Figure 32 Yellow colour fruit is riped fruit and green colour fruit is unriped fruit. 
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Figure 33 Dried fruit of Garcinia atroviridis which is also known as ‘asam keping’. 
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The leaves of Garcinia parvifolia were collected from the lowland dipterocarp, Sungai 
Congkak Reserve Forest in Malaysia and a voucher specimen (45L) was deposited at the 
Herbarium of The University of Nottingham, Malaysia Campus. 
 
Figure 34 Garcinia Parvifolia with unriped fruit 
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4.2 Extraction Results 
 
4.2.1 Extraction Yields 
Table 2 represents the yield of extraction for different plant parts of Garcinia atroviridis 
which are leaves, twigs and fruits and leaves parts of Garcinia parvifolia. All of these plant 
parts were extracted using different polarity which ranging from low polarity to high polarity 
of organic solvent. 
 
Table 2 Yield of Extraction of Garcinia atroviridis and Garcinia parvifolia.  
Scientific 
name  
Plant 
part 
Code Dried 
weight 
(g) 
Solvent 
used for 
extraction 
(ml) 
Extracts Percentage 
yield 
Garcinia 
atroviridis 
 
Leaves 
 
78L 1596  
12784 
Hexane 9.3 
Ethyl 
Acetate 
10.1 
Ethanol 13.8 
 
Twigs 
 
78T 
 
1109 
 
8872 
Hexane 8.4 
Ethyl 
Acetate 
10.3 
Ethanol 12.7 
Fruit 78F 865 6920 Hexane 5.6 
Ethyl 
Acetate 
6.1 
Ethanol 8.0 
Garcinia 
parvifolia 
Leaves 45L 437 3496 Hexane 3.4 
Ethyl 
Acetate 
4.1 
Ethanol 5.0 
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The extraction yield of the plants is highly depending on the solvent polarity which will later 
determines both quantitatively and qualitatively the extracted compound. Based on the table 
2, three solvents with increasing polarity had been used in the maceration process which is 
Hexane, Ethyl Acetate and Ethanol. The highest percentage yield obtained is from Ethanol 
extracts of all plant species and the lowest percentage yield is obtained from Hexane extracts 
of all plant species. 
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4.3 Phytochemical screening of crude extract 
 
In order to understand the possible compounds that might be present in the plant species, 
various phytochemical screening had been carried out.  
 
In order to predict the presence of alkaloids, flavonoids, saponin, tannin, steroid, terpenoid 
and phytosterol content in the extracts, phytochemical screening of UNMC 78L, UNMC 78T 
and UNMC 78F had been carried out and the result can be shown in table below. The results 
of phytochemical screening of UNMC 45L can be obtained from Wong et al. (2012). 
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Table 3 Phytochemical screening of UNMC 78T 
Extracts Alkaloids Flavonoids Saponin Tannin Steroid Terpenoid Phytosterol 
Hexane - ++ - + ++ + ++ 
Ethyl Acetate - - - ++ - - + 
Ethanol + - + - + + - 
                 ++ highly present  
                 + slightly present 
                 - not present at all  
 
Based on table 8, more secondary metabolites are present in the Hexane extracts of UNMC 78T compare to the ethyl acetate extracts and ethanol 
extracts of UNMC 78T. Based on the table above, flavonoids, tannin, steroid, terpenoid and phytosterol present in the hexane extract. For the 
ethyl acetate extracts, only tannin and phytosterol does present in the extracts. Alkaloid, saponin, steroid and terpenoid were present in the 
ethanol extracts of UNMC 78T. 
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Table 4 Phytochemical Screening of UNMC 78L 
Extracts Alkaloids Flavonoids Saponin Tannin Steroid Terpenoid Phytosterol 
Hexane - ++ - - ++ + + 
Ethyl Acetate - + - ++ + ++ - 
Ethanol + - + - - - ++ 
        ++ highly present  
        + slightly present 
        - no present at all  
Positive results of flavonoids, steroid and terpenoid can be seen with the Hexane and Ethyl Acetate extracts of UNMC 78L. Ethyl Acetate 
extracts of UNMC 78L contains tannins which does not present in both Hexane extracts and ethanol extracts. Phytosterol does presents in both 
Hexane and Ethanol extracts. Conversely, only the ethanol extracts of UNMC 78L revealed the presence of saponin and alkaloids composition in 
the screening.  
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Table 5 Phytochemical screening of UNMC 78F 
Extracts Alkaloids Flavonoids Saponin Tannin Steroid Terpenoid Phytosterol 
Hexane - ++ - ++ - - - 
Ethyl Acetate - - + + - - - 
Ethanol ++ ++ + - - - + 
        ++ highly present  
        + slightly present 
        - not present at all  
 
The table above (table 10) shown that Ethanol extracts contain alkaloids, flavonoids, saponin and phytosterol while Ethyl acetate extracts slightly 
contain saponin and tannin. Hexane extracts only contains flavonoids and tannin. 
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4.4 Optimizing and development of Cholesteryl Ester Transfer Protein 
Assay  
4.4.1 Development of Cholesteryl Ester Transfer Protein Assay 
One of the main objectives of this study is to develop a protocol in order to see the 
inhibition activity of the crude extracts and other possible inhibitor against CETP 
activity. The basic principle of the CETP assay is based on fluorometric reading at 
which it contains donor molecule and acceptor molecule. Donor molecule contains 
fluorescent self-quenched neutral lipid which will be transferred to acceptor molecule 
in the present of CETP. The successful transfer will cause increase in the fluorescent 
intensity value while presence of inhibitor will reduce the fluorescent intensity reading.  
There is no literature up-to-date that uses the CETP drug screening kit in natural 
product research drug discovery. No reference can be made on the optimal conditions 
that could be used in the experiment. Hence, several attempts on optimization of the 
assay kit were carried out to establish a new method for this research purpose. 
 
The important parameter in this optimization of assay is the incubation time. This 
CETP screening assay kit needs to be incubated at certain period of time specifically 
according to the human basal body temperature which is 37⁰C. Several tests had been 
done at different incubation times which are 30 minutes, 40 minutes, 50 minutes, 60 
minutes and 90 minutes. 
 
It is being reported that 1,3,5-triazines were found to be potent towards CETP (Xia et 
al, 1999). And, in this study to optimize the CETP drug screening kit, 10uM of 1,3,5-
triazine had been used to assess the optimal time of reaction.  
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Figure 35 Different incubation time of 1,3,5-triazine against CETP inhibition. Each 
point represent the mean ± standard deviation from three different independent 
experiment (n=3) P<0.05. 
 
Based on the figure 35, the suitable incubation time is 60 minutes and this value 
correspond towards the IC50 of the 1,3,5-triazine (Okamoto et al., 2000). Less 
incubation time might lead to incomplete reaction between the donor molecule and 
the acceptor molecule. It is important to incubate the samples at the appropriate 
incubation time as this will produce better accuracy in the percentage of inhibition 
due to the facts that perfect time taken for incubation will leads to complete 
reactions of the sample. Besides, prolong incubation time might cause the reaction to 
be “saturated” which will lead to the loss of activity and the fluorescence intensity 
reading is not accurate anymore (Foti and Fisher, 2004). 
 
The percentage inhibition of the extracts towards CETP activity was calculated as 
follows: 
Percentage Inhibition
= (1 − [
sample read − blank read
Positive control read − Negative control read
]) x 100 
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Tested Sample 
50 μl of inhibitors or 
crude extracts. 
3μl of rabbit serum 
100 μl of distilled H20 
 
Negative Control  
50 μl of inhibitors or 
crude extracts. 
100 μl of distilled H20 
 
Positive Control 
50 μl of 0.1% DMSO 
3μl of rabbit serum 
100 μl of distilled H20 
 
ADD MASTER MIX 
10μl Donor molecule 
10μl Acceptor molecule 
20μl CETP buffer 
 
 
Shake for 1 
minute 
Incubate for 1 hour at 37°C 
Shake for 1 
minute 
Plate reader reads at 465nm for 
Excitation wavelength and 
535nm for Emission wavelength 
Figure 36 Summary of CETP assay 
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4.4.2 CETP inhibitory assay for all plant extracts 
 
After the optimization of CETP has been done, further CETP inhibitory assay being 
done involving all the extracts of UNMC 78, UNMC 45L and one crystal product 
that was being isolated from UNMC 45L which is known as clusianone (Wong, 
2013). A higher inhibition activity of CETP assay is being indicated by a lower 
value of IC50, is anticipated as an active inhibition. The results are being described 
below. 
 
4.4.2.1 Inhibition of extracts from UNMC 78T against CETP activity 
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Figure 37 Percentage inhibition of UNMC 78T against CETP activity. Each 
points represent the mean ± standard deviation from three independent 
experiment (n=3) P<0.05. 
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Table 6 IC50 of UNMC 78T plant extracts 
Plant Extract 
UNMC 78T 
IC50 
Hexane 89.67 ± 0.035 mg/ml 
Ethyl acetate 94.25 ± 0.002 mg/ml 
Ethanol Cannot be 
determined 
 
The three extracts of UNMC 78T with different polarity which are Hexane, Ethyl 
Acetate and Ethanol were screen to assess their inhibitory effect against CETP 
activity. The IC50 for hexane extract and ethyl acetate extract are 89.67 ± 0.035 
mg/ml and 94.25 ± 0.002 mg/ml respectively. These values considered very high 
since it almost reach 100mg/ml. However, the IC50 of ethanol extract of UNMC 78T 
cannot be determined at the concentration studied.  
 
This reveals that extraction by using both low polarity and intermediate polarity 
solvents were the best in extracting the secondary metabolites from UNMC 78T that 
are actively inhibits CETP activity. In agreement with earlier results of UNMC 78T, 
hexane and ethyl acetate have been generally described as most suitable solvents for 
extraction that recover flavonoids and phytosterol. These phytochemicals have been 
investigated and they does have the properties as a cardioprotective  effects (Cook & 
Samman, 1996; Testai et al., 2013; Yoshida & Niki, 2003). 
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4.4.2.2 Inhibition of extracts from UNMC 78L against CETP activity 
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 Figure 38 Percentage inhibition of UNMC 78L against CETP activity. Each 
point represent the mean ± standard deviation from three independent 
experiment (n=3) P<0.05. 
 
Table 7 
IC50 of UNMC 
78L plant 
extracts 
 
 
 
 
 
All of the plant extracts of UNMC 78L, which are Hexane and Ethyl Acetate, and 
Ethanol undergoes screening to detect its inhibitory effect against CETP. Hexane 
extracts show the highest potency compared to the other extracts followed by Ethyl 
Acetate extract and Ethanol extract shows the lowest potency among other extracts. 
The IC50 for all the extracts are presented in the table above. All of the extracts 
Plant Extract 
UNMC 78L 
IC50 
Hexane 54.83 ± 0.027 mg/ml 
Ethyl acetate 59.01 ± 0.003 mg/ml 
Ethanol 62.47 ± 0.005 mg/ml 
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shows a gradual increase in the percentage of inhibition as the concentration of the 
extract increases. 
 
Percentage inhibition of UNMC 78L against CETP activity does produce the same 
percentage inhibition trend as UNMC 78T where the most potent extracts is hexane 
extracts and least potent is ethanol extracts. Based on the analysis of IC50, small 
differences of the value of IC50 can be observed between the three extracts with 
different polarity. The higher potency of hexane extracts and ethyl acetate extracts is 
due to the present of flavonoids, steroids and terpenoids in the extracts and these 
phytochemicals might present as an active ingredient that acts towards inhibition of 
CETP activity.  
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4.4.2.3 Inhibition of extracts from UNMC 78F against CETP activity 
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Figure 39 Percentage inhibition of UNMC 78F against CETP activity. Each point 
represent the mean ± standard deviation from three independent experiment (n=3) 
p<0.05. 
 
Table 8 IC50 of UNMC 78F plant extracts 
Plant Extract UNMC 78F IC50 
Hexane 41.23 ± 0.007 mg/ml 
Ethyl acetate 35.79 ± 0.003 mg/ml 
Ethanol 19.28 ± 0.021 mg/ml 
 
Three extracts of UNMC 78F were initially screened on the inhibitory effects towards CETP 
activity. IC50 values were determined and being listed in the table 8. Among these three 
extracts, ethanol extracts of UNMC 78F appeared to be more potent compared with hexane 
extract and ethyl acetate extract. This finding gives some interesting insight since the values 
obtained for the percentage inhibition of ethanol extracts from UNMC 78F is considered to 
be very potent compared to the other extracts of different plant parts of UNMC 78 because 
less amount of ethanol extracts of UNMC 78F is needed to obtain 50 percent effect. Thus, 
therapeutic preparations of drugs will reflect the potency.  
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In the present works, UNMC 78F shows a remarkable effects against the CETP activity. This 
being indicated by the lowest values of IC50 compared to other extracts. This findings suggest 
that extraction using high polarity solvent is the most effective way in extracting the active 
secondary metabolites from UNMC 78F. This results is well supported by other studies 
which suggest the important bioactive compound that present in UNMC 78F which is 
Hydroxycitric acid (HCA) are being extracted by using higher polarity solvents (Lewis, 
1965). 
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4.4.2.4 Inhibition of extracts from UNMC 45L against CETP activity 
0 20 40 60 80 100
0
20
40
60
80
100
concentration (mg/ml)
P
e
rc
e
n
ta
g
e
 i
n
h
ib
it
io
n
 (
%
)
hexane extract
ethyl acetate extract
ethanol extract
 
Figure 40 Percentage inhibition of UNMC 45L against CETP activity. Each point 
represent the mean ± standard deviation from three independent experiment (n=3) 
p<0.05. 
 
Table 9 IC50 of UNMC 45L plant extracts 
Plant Extract UNMC 45L IC50 
Hexane 97.35 ± 0.0045 mg/ml 
Ethyl acetate 98.72 ± 0.0032 mg/ml 
Ethanol 96.24 ± 0.0028 mg/ml 
 
Based on the figure 40, all of the UNMC 45L crude extract exhibit minimal inhibitory effect 
since all of the extracts have the almost similar IC50 values and these value cannot be 
determined as potent compared to crude extracts from UNMC 78 plant species. This is 
because the values obtained for the IC50 is almost 100mg/ml and this values considered very 
high. The higher the IC50 values, the less potent the extracts is. The IC50 values of the plant 
extracts can be summarized above. 
 
Preliminary screening of UNMC 45L shows that all of the extracts can inhibit CETP 
however, the results are not that potent compared to UNMC 78. The lowest value of IC50 is 
104 
 
ethanol extracts followed by hexane extracts and ethyl acetate. This might be due to the 
presence of certain secondary metabolites that are being extracted via hexane, ethyl acetate 
and ethanol extracts from UNMC 45L is not highly active in the inhibition of CETP activity. 
Although same solvents is being used as in previous extraction of UNMC 78T, UNMC 78L 
and UNMC 78F but different activity is being observed due to specific compounds that might 
present in one species and not in other species.  
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4.4.2.5 Inhibition of Clusianone (Pure compound isolated from UNMC 45L) against 
CETP activity 
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Figure 41 Percentage inhibition of clusianone against CETP activity. Each point 
represent the mean ± standard deviation from three independent experiment (n=3) 
P<0.05. 
Clusianone, a pure crystal compound found in hexane extracts of UNMC 45L (Wong, 2013) 
had been tested for CETP inhibition.  Large numbers of polyisoprenylated benzophenone 
have been isolated from Guttiferae (Clusiaseae) family and clusianone and its derivatives are 
considered as polyisoprenylated benzophenone. Several studies have proven that 
benzophenone and its derivatives does have important bioactivity such as anti lipogenic, anti-
cancer, anti-oxidant, anti-inflammatory, and anti-ulcer (Kumar et al., 2013; K. Yoshida et al., 
2005). Due to this interesting bioactivity, it is important to see the efficiency of clusianone 
tested against CETP activity.  
 
Various concentration had been used to see the effect against CETP. However, no effective 
inhibition can be seen from lowest to the highest concentration of clusianone and the 
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percentage inhibition does not reach 50% inhibition. Due to this reason, IC50 of clusianone 
against CETP inhibition cannot be determined. The results obtained are quite disappointing 
as the IC50 of clusianone cannot be determined. From this observation, clusianone is not an 
effective inhibitor towards CETP at this range of concentration. However, final conclusion 
cannot be drawn based on these ranges of concentration, as there are some limitations. The 
possible reason is it that clusianone might target specific protein to react since it does not 
inhibit CETP in this amount but possible to inhibit HMG-CoA reductase with this range of 
concentration (Wong,2013).  
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4.4.2.6 Inhibition of Hydroxycitric Acid against CETP activity. 
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Figure 42 Percentage inhibition of Hydroxycitric acid (HCA) against CETP activity. 
Each point represents the mean ± standard deviation from three independent 
experiment (n=3) P<0.05. 
 
This study was initiated after we discovered the highest inhibition of crude fruit rind extracts 
of Garcinia atroviridis against CETP activity via the CETP inhibitory assay. Based on 
several literatures (Jena et al, 2002, Hobbs, 1994), HCA is the principal compound that acts 
as a potent inhibitor of ATP citrate lyase which catalyzes the extramitochondrial cleavage of 
citrate to oxaloacetate and acetyl-CoA: citrate + ATP + CoA acetyl-CoA + ADP + Pi + 
oxaloacetate (Daikuhara et al., 1968). The inhibition of this reaction limits the availability of 
acetyl-CoA units required for fatty acid synthesis and lipogenesis during a lipogenic diet, that 
is, a diet high in lipids (Sullivan et al., 1972). Extensive animal studies indicated that (-)-
HCA suppresses the fatty acid synthesis, lipogenesis, food intake, and induced weight loss 
(Sullivan et al., 1972). Several studies have confirmed that HCA does not bring short term 
and long term bad effect. One of the studies uses variable time length which is 4 to 30 days 
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and doses taken are from 150mg to 1500mg of pure compound but no one has ever reported 
about toxicity of HCA (Leonhardt et al., 2004; Leonhardt et al., 2001; Rao & Sakariah, 1988) 
Several form of readily available product that contains HCA can be found commercially such 
as Regulator®, Citrin K® and SuperCitrimax® (Preuss et al., 2006). Based on this, the initial 
assumption is HCA is also responsible for inhibiting the CETP activity.   
 
Based on the CETP inhibitory assay that was being graphed in figure 42, the IC50 of HCA 
inhibition against CETP is 20.07 ± 0.05 μM.  This value indicates that HCA is a potent 
inhibitor towards CETP activity. From this assay, HCA has been identified as a potential 
inhibitor for CETP. This significant results for CETP inhibition is important and need to be 
further validated in series of in-silico techniques which are being discussed later in this 
chapter.  
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4.5 Determination of enzyme reaction: Designing and Optimizing enzyme 
kinetics assay 
4.5.1 Kinetic properties of HCA against CETP activity 
Every inhibitor might have different inhibitory mechanisms against the protein of interest 
(Copeland, 2000).  There are four main types of inhibition; competitive inhibition, non-
competitive inhibition or mixed, uncompetitive inhibition and mechanism-based inactivation 
or also being called as suicide mechanism.  This study is important to assess the inhibitory 
mechanism of HCA against CETP. Only kinetic study of HCA has been carried out since it 
shows the highest inhibition rates.  
 
In order to evaluate the mechanism of inhibition between CETP and HCA, enzyme kinetic 
study was being done. However, there are no reported kinetic assay procedures has been done 
by using the assay kit. The same assay kit that was being used in the screening assay was also 
use in this experiment and the same protocols had been applied except that the readings were 
taken every 1 minute interval during the 60 minutes incubation period.  
 
The kinetic assay is being done based on Michealis Menten equation in order to determine 
the Km value and the maximum reaction rate which is Vmax using Lineweaver-Burke plot.  
Vo = 
Vmax [s]
Km + [s]
 
 
The type of inhibition with the values of Ki can be determine from Lineweaver-Burke plot or 
double reciprocal plot. This is important to know the properties of the inhibitors and the 
mechanism of reaction between the inhibitors and the protein in order to know the 
effectiveness of the inhibitor.  
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Several concentrations have been tested to see their kinetic properties every 1-minute interval 
for 60 minutes duration. 
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Figure 43 Progress curve for kinetic assay of HCA against CETP. Each point represents 
the mean ± standard deviation from three independent experiment (n=3) P<0.05. 
 
 
Progress curve from figure 45 shows that as the time passed by the absorbance increase 
resulting in the formation of the by product. But when it started to reach 30 minutes, the 
absorbance remains constant which indicates that the maximum incubation times has taken 
place. 
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Figure 44 Lineweaver-burk analysis of HCA inhibition kinetic assay. 
 
Further analysis by using Michaelis-Menten equation through the double reciprocal plots or 
Lineweaver-burk analysis in figure 44, suggested that HCA is a non-competitive inhibitor 
against CETP. Noncompetitive inhibitor or allosteric inhibition is an inhibitor which binds to 
enzymes regardless of substrate binding.  This can be seen in the Lineweaver-Burk plot in 
figure 44,  whereby the Km is unchanged for every substrate concentration and the Vmax 
which is the slope is increased when the concentration of the inhibitor increase. The 
mechanism of action of HCA is the same as that torcetrapib, where it has been proven to be 
non-competitive inhibitor through traditional biochemical method (Clark et al., 2006). The 
results obtain from enzyme kinetic assay can be used as a supporting data for molecular 
modeling experiment which later can predict the specific interaction of the inhibitor and the 
active site.  
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4.5 Validation of HCA presence in ethanol crude extracts of UNMC 78F 
 
4.5.1 Validation by using FTIR method 
The spectra of the G. atroviridis fruit rind (UNMC 78F) macerated with ethanol solvent 
provide a number of spectral details indicating some similarities with each other. From the 
FTIR spectra analysis, all significance functional groups were present. The existence of 
carboxylic acid, esters and hydroxyl group indicated high probabilities of the HCA content in 
the concentrated crude extract of  G. atroviridis  fruit rind (UNMC 78F) (Jena et al., 2002). 
The absorbance peaks of the spectra and data can be seen in Figure 45 and Table 10, 
respectively. 
 
4.5.1.1 Hydroxyl (OH) bands 
The OH stretch value for ethanol extracts of UNMC 78F were fitted within the range 3550 
cm-1 to 3200 cm-1. The O-H band value in ethanol extracts of UNMC 78F is 3405.17 cm-1 
(Figure 45). However, it can be seen that the OH band spectra were broad and less peaky, this 
may due to different signal arise from vibrations of molecules, as the identification of 
hydroxyl and carboxyl group require O-H stretch. This situation leads to broadening and 
overlapping bands of spectra (Schmitt and Flemming, 1996). 
 
4.5.1.2 Carboxyl (COOH) bands 
According to the  standard IR spectra table, the present of carboxyl group in the sample can 
be deduced as long as the O-H,  C=O and C-O stretch lie in between the value of 3200 cm-1 – 
2500 cm-1 , 1725 cm-1 – 1700 cm-1 and 1300 cm-1-1000 cm-1, respectively. The C=O stretch of 
carboxyl group depicted sharply at 1720.52 cm-1 for the sample macerated in ethanol extracts 
of UNMC 78F. The C-O stretch were shown at 1200.27 cm-1 and 1062.1 cm-1. Both values 
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fall in C-O stretch standard range, which arise the probability one of the value is specific to 
the carboxyl group. It is proven that the range below 1500 cm-1 can be very specific for a 
substance or for different types of substitution. This range is frequently referred to as the 
“fingerprint region” of a spectrum (Diem, 1994; Urban, 1994; Schrader, 1995 in Schmitt and 
Flemming, 1996). Since the C=O and C-O stretch between carboxyl group and esters close in 
range, the way to detect the presence of the carboxyl groups is by confirming the O-H stretch 
which is absent in esters. Thus, the O-H stretch must be within the range of 3200 cm-1-2500 
cm-1. From the spectra absorbance peak, O-H stretch mildly depicted at the value 2922.41 
cm-1 for ethanol extracts. Hence, as the value for O-H, C=O and C-O stretches fall within the 
standard range, it can be deduced that carboxyl groups exist in the sample. 
 
4.5.1.3 Esters bands 
The present of esters can be verified from the C=O and C-O stretch peaks. In this experiment, 
the spectra absorbance peaks between esters and carboxyl groups resembled within the same 
range. However, the O-H stretch absorbance peaks that only exist in carboxyl group and two-
specific absorbance below 1500 cm-1 relatively belong to either one of the groups can be a 
good inference in verifying their presence, as in FTIR, different forms of vibrations are 
discriminated, arising from different forces and binding angles of atoms in a molecule. Thus, 
complex molecules display numerous options of internal vibrations (Schmitt and Flemming, 
1996). As in carboxyl groups, the C=O stretch of esters in ethanol extracts  fall in between 
1730 cm-1-1715 cm-1. The possible value of absorbance peak for C-O stretch binding in 
esters, 1199.08 cm-1 and 1062.1 cm-1 in ethanol extracts. The strong band for both stretches 
can be good base to conclude the existence of esters in this sample.
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Figure 45 FTIR Absorbance peaks for ethanol extracts of UNMC78F 
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Table 10: Tabulated position of absorbance peaks 
 
Vibration 
 
Position (cm-1) 
Standard Sample extracted by 
ethanol 
Alcohols/Hydroxyl 
O-H stretch 
 
 
3550-3220 
 
3405.17 
Carboxyl group 
O-H stretch 
C=O stretch 
C-O stretch 
 
 
3200-2500 
1725-1700 
1300-1000 
 
2922.41 
1720.52 
1200.27/1062.69 
Esters 
C=O stretch 
C-O stretch 
 
1730-1719 
1300-1000 
 
1720.52 
1200.27/1062.69 
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4.5.2 Validation by using HPLC method 
 
HPLC method has been employed in this chapter in order to validate the presence of HCA in 
ethanol crude extracts of UNMC 78F. Two chromatogram can be seen in figure 46 and 47.  
One clearly resolved peak  were obtained in each chromatogram  where the retention time of 
HCA in standard is 1.069 minute in figure 46 and the peak obtained from ethanol extracts of  
UNMC 78F is  1.106  minute in figure 47. 
 
The results were comparable since the peak of the ethanol extracts of UNMC 78F was 
appeared in the same timescale as the standard.   Two small peak also appeared in the crude 
extract of UNMC 78F in figure 47 indicates that other compound also present in the sample.  
The results in figure 47 which shows that HCA is the major organic acid that is found in the 
fruit sample of UNMC 78F since it was resolved as a single peak with no interference from 
other compound.  The identity of HCA peak was confirmed by determination of relative 
retention time and by spiking with standard HCA. The retention time of HCA in this 
experiment is also being confirmed by other publication as well (Jayaprakasha and Sakariah, 
1998; Ibnusaud et al., 2000; Jena et al., 2002;Jayaprakasha and Sakariah,2002; Asish et al., 
2008, Kumar et al.,  2013; Upadhyay et al., 2013 ). 
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Figure 46 Chromatogram of HCA standard. The peak can be seen at Rt= 1.089 minute 
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Figure 47 Chromatogram of ethanol extract of UNMC 78F. The peak can be seen at Rt= 1.166 minutes, 1.303 minutes, 1.861 minutes 
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4.6 Validation of HCA inhibition using molecular docking study 
Molecular modeling has been used in the next part of the thesis in order to validate the 
screening result and also to see the interaction between the inhibitor and CETP virtually.  
This study does not aim to find the possible binding poses of HCA but it is to show the most 
suitable binding sites for HCA. By using GLIDE (Grid-based ligand docking with energetics) 
molecular docking software which uses hierarchical filter in order to search for the best 
position of the inhibitor with the active site of the protein. This software is the best in order to 
search the most probable binding sites of crystal structure of CETP at which HCA would 
favour to bind at.  
 
Based on the previous study done by Liu et al. (2012), crystal structure of torcetrapib bounds 
to CETP binding site has been obtained and PDB (Protein Data Bank) identification for this 
structure is 4EWS. Based on this crystal structure, torcetrapib bounds inside the CETP tunnel 
and this binding site is used as reference for the molecular docking study of HCA against 
CETP.  
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CETP tunnel 
CETP tunnel 
Figure 48 (a) Image of CETP using solid surface setting in PyMol. (b) Sliced 
image of CETP where the tunnel is being labelled in red box.  
(a) 
(b) 
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Figure 49 Ribbon view of docking pose of HCA against CETP. The structure of HCA is 
indicated as the stick view. 
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Figure 50 2D representation of the ligand-receptor interaction between HCA and 
residue model obtained from docking using Glide showing hydrogen bonds involving 
backbone atoms (solid purple arrows) and hydrogen bonds involving side-chain atoms 
(dashed purple arrows). Polar and hydrophobic residues are depicted with light blue 
and green circles respectively.  
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Figure 51 3D representation of HCA and residues that involve. The yellow dashed line 
indicated the hydrogen bonding of HCA with HIS232 and SER230.  
 
Based on the Molecular docking results by using GLIDE, multiple poses has been generated 
but one best pose has been chosen. The best pose has been taken into account based on the 
reading of GLIDE gscore and GLIDE emodel. GLIDE gscore is an empirical scoring 
function that approximates the ligand binding free energy. GLIDE e model is a significant 
weighting of the force fields components (electrostatic and Van Der Waals energies). GLIDE 
basically use Emodel in order to choose the best pose of a ligand and will rank the best poses 
against one another with GLIDE score. So, GLIDE emodel can be summarized as scoring 
based on GLIDE score, internal ligand strain (External) and Coulomb and Van Der Waals 
energy.  
Table 11 Docking result of HCA from GLIDE 
GLIDE gscore -4.573 
GLIDE 
emodel 
-31.665 
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The best pose and docking score for molecular docking of HCA to CETP are being 
summarized in table above.  The GLIDE g-score reading is -4.573 and the GLIDE emodel 
value is -31.665. The GLIDE g-score that is being indicated in table 11 above shows the sum 
of the individual H-bond scores for H-bonds between the ligand and given residue. The more 
negative the score the stronger the H-bonding. Based on our results the negative values that 
was being obtained indicate that the H-bonding between HCA and CETP is strong. Based on 
this experiment, multiple poses has been generated and GLIDE emodel helps in picking up 
the ‘best’ pose of a ligand. The results obtained in this experiment is the best rank among 
other poses.  
 
Based on figure 51, there are still large space left in the N pocket after HCA binding and C 
pocket are remain undisturbed. This suggests that HCA entered the tunnel through N-terminal 
opening. CETP tunnel are hydrophobic in nature and HCA is deeply buried inside the 
hydrophobic tunnel of N terminal. Based on the ligand receptor interaction figure, HCA is 
occupying the pocket formed by side chains of PHE263, VAL198, GLN199, ILE215, 
CYS13, ILE15, HIS232, VAL136, SER230 and LEU217. All of the side chain residues are 
hydrophobic at which PHE263 are being remarked as hydrophobic neck of the tunnel except 
for these three residues which are GLN199, SER230, and HIS232 which is a polar residues. 
Due to this properties, HCA forms hydrogen bonding towards SER230 and HIS232. This 
hydrogen bonds helps in the stability of the bonding of HCA towards CETP tunnel. 
 
In order to revalidate the producibility of GLIDE docking data, rescoring by using GOLD 
suites has been implemented. The usage of GOLD has been employed since it is using 
different scoring matrices and different algorithm. The idea of revalidation of using different 
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docking software is to see whether HCA does bind to the same site when different docking 
software has been use. The score that provide the same binding site with the same residue 
through GOLD suites indicates that the GLIDE data are reproducible. The best Chemscore 
value obtained is 38.6 and it does shows the same binding site and residues compared to 
GLIDE results. 
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Figure 52 3D superimposed image of HCA and torcetrapib where blue colour stick 
indicates torcetrapib and green colour stick is HCA. 
 
Figure 53 3D mesh surface of superimposed image of torcetrapib (blue colored stick) 
and HCA (green colored stick) 
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Figure 54 Enlarged image of superimposed torcetrapib (blue colored stick) and HCA 
(green colored stick) 
 
The solved crystallised structure (PDB ID: 4EWS) with known inhibitor, Torcetrapib had 
been use as reference for its binding site. The structure had been loaded into Pymol and 
command script ‘align’ has been used to create superimposed image of Torcetrapib and 
HCA. Based on figure 52to figure 54, torcetrapib and HCA bounds at the same side although 
both of them have huge differences in structure. The (Root Mean Square Deviation) RMSD 
value that is being obtained through alignment is 2.703Å. The RMSD measures how 
difference the two ligands which are HCA and torcetrapib. The smaller the values of RMSD 
indicates how closer and similar the ligands. Based on this result, the value obtained is 
expected for this structure (Koike et al., 2008). 
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4.7 Molecular dynamic study of HCA inhibition. 
 
Analysis through molecular dynamic study has been done as part of this thesis in order to see 
the stability of the HCA-CETP complex that is being immersed in explicit water molecules in 
nanosecond time scale. In this dynamic study, the complex are being tested in equilibrium 
state at which large scale motions are absent but they are still free to move but not in any 
specific direction (Zeiske et al., 2016). This is important to see whether the HCA-CETP 
complex is still bind to each other when the molecular dynamic condition is being applied for 
the duration of 20ns timescale.  
 
In this work, the interaction between CETP and HCA were studied. The system used is the 
HCA-CETP complex and MD simulations were performed with 10ns and 20ns. The main 
purpose for this study is to see the overall stability of the system in nanosecond time scale 
based on the Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation 
(RMSF) that obtained. 
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Figure 55 RMSD value for 20ns simulation run 
Protein RMSD: In figure 55, shows the RMSD values of a protein (left Y-axis). All protein 
frames are first aligned on the reference frame backbone, and then the RMSD is calculated 
based on the atom selection in the system. Monitoring the RMSD of the protein can give 
insights into its structural conformation throughout the simulation. The overall structure of 
HCA-CETP complex appeared to be equilibrated less than 5ns as deciphered by the plot in 
figure 45 and figure 46. The backbone net displacement which is measured as α-carbon 
RMSD reach almost plateau reading after 5ns. The overall RMSD reading are range between 
0.8 Å, 2.4 Å and the highest is 3.2 Å. The values seems to stabilize around a fixed value 
meaning that the system are already being equilibrated. The RMSD values does not fluctuates 
and seems to stabilize around fixed values which means that the system are fully equilibrated. 
Ligand RMSD: Ligand RMSD (right Y-axis) indicates how stable the ligand is with respect 
to the protein and its binding pocket. In the above plot, 'Lig fit Prot' shows the RMSD of a 
ligand when the protein-ligand complex is first aligned on the protein backbone of the 
reference and then the RMSD of the ligand heavy atoms is measured. The values obtained for 
ligand RMSD are almost similar to the protein RMSD indicates the stability of the HCA 
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binding. 
 
 
Figure 56 RMSF value for CETP during 20ns simulation run 
The Root Mean Square Fluctuation (RMSF) analysis is used to characterizing changes along 
the protein chain throughout the simulation run. On this plot in figure 56, most of the RMSF 
values for amino acid fluctuates between 1.2 Å to 3 Å, but there is also some amino acid that 
fluctuates higher than that.  
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Figure 57 Histogram of Secondary Structure Element (SSE) for every amino acid 
residue in CETP during simulation run. The orange region corresponds to the alpha 
helix and the blue region corresponds to the beta sheets of CETP. 
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Figure 58 SSE analysis like alpha helices and beta strands are monitored throughout of 
the simulation trajectory where top panel shows the percentage of SSE over 20ns 
simulation time and bottom panel monitors each amino acid residue over time.  The 
blue region corresponds to beta sheets and the orange region corresponds to alpha helix 
strands of CETP.
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Figure 59 Protein interaction diagram with the ligand throughout the simulation run. 
The green, purple, pink and blue indicates hydrogen bonds, hydrophobic bonds, ionic 
bonds and water bridges, respectively. 
  
The protein interaction diagram are shown above where the interaction can be categorized 
into four types such as Hydrogen Bond, Hydrophobic bond, Ionic bond and water bridges. 
Hydrogen bond can be largely seen on SER 230 and GLN 199. Small traces of hydrogen 
bond can be seen on ARG 201. Hydrophobic bonds interaction can be seen at residue ILE 15, 
VAL 136, VAL 198, ALA 202 and LEU 228. Small traces of ionic interaction can be seen at 
ARG 201. Water bridges interaction can be seen at residue VAL 136, ALA 195, VAL 198, 
ARG 201 and HIS 232. 
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Figure 60 Summary of interactions between residues over 20ns simulation run. There is 
a total of 6 contacts that has been made throughout the 20ns simulation run and this 
can be seen on the top panel of the figure. The X values of the bottom panel of the 
figures indicates the time taken for the overall simulation run and the Y values shows 
the residues that is involves. The values in the middles corresponds to the number of 
contacts based on the colour intensity. 
 
 
Protein-Ligand Contacts (cont.)
A timeline representation of the interactions a d contacts ( H-bonds, Hydr phobic, Ionic, Water bridges)
summarized in the previous page. The top panel shows the total number of specific contacts the protein
makes with the ligand over the course of the trajectory. The bottom panel shows which residues interact with
the ligand in each trajectory frame. Some residues make more than one specific contact with the ligand,
which is represented by a darker shade of orange, according to the scale to the right of the plot.
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Figure 61 Summary of ligand properties throughout 20ns simulation time which 
includes Ligand RMSD, radius of Gyration (rGyr), intramolecular hydrogen bonds, 
Molecular surface area (MolSA) Solvent accessible surface area (SASA) and Polar 
surface area (PSA). Ligand RMSD: RMSD value indicates the root mean square 
deviation of a ligand based on the time t=0 which is regard as reference time. Radius of 
Gyration (rGyr): Based on the principal moment of inertia and it measures the 
“extendedness” of ligand. Intramolecular Hydrogen Bonds (intraHB): Number of 
internal hydrogen bonds (HB) within a ligand molecule. Molecular Surface Area 
(MolSA): This value equivalent to Van der Waals surface area. Solvent Accessible 
Surface Area (SASA): Considered as a surface area of a molecule accessible by a water 
molecule. Polar Surface Area (PSA): Solvent accessible surface area in a molecule 
contributed only by oxygen and nitrogen atoms.  
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1st pocket 2nd pocket HCA 
Figure 62 Screenshot of MD simulation starting from 0ns to 20ns. There are two pockets that is being coloured 
purple. The first pocket is the place where HCA is situated before simulation run and the second pocket is the place 
where HCA is situated after 20ns simulation run. The purple colour stick structure is HCA 
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                                     0ns 
 
 
                                        20ns  
Figure 63 2D representation of the ligand-receptor interaction between HCA and 
residue model obtained from docking using Glide during 0ns and 20ns simulation run, 
showing hydrogen bonds involving backbone atoms (solid purple arrows) and hydrogen 
bonds involving side-chain atoms (dashed purple arrows). Polar and hydrophobic 
residues are depicted with light blue and green circles respectively.  
                                              
 
Based on figure 62 the ligand does show stable bonding inside the CETP tunnel. This can be 
proven when HCA does not move outside the tunnel whenever pressure was applied for 20ns 
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timescale during the MD simulation. This indicate the stability of the HCA-CETP complex 
(Alonso et al., 2006). And based on the figure 63, the comparison of the ligand interaction 
can be seen between before and after MD simulation. At 0ns, HCA forms hydrogen bonding 
between SER230 and HIS232. And after 20ns of MD simulation, HCA forms hydrogen 
bonding between GLN199 and SER230. And based on this analysis, HCA does not deviate 
too far and the hydrogen binding to SER230 shows the stability of the complex. 
 
These simulations run give rise to valuable new predictions about the dynamics of HCA-
CETP complex and provide meaningful insights in general into the reliability and 
reproducibility of the molecular modeling methods. Overall, the results of HCA binding 
towards CETP are very encouraging. 
 
 
 
 
 
 
 
 
 
 
4.8 Structure activity relationship study of HCA analogues. 
The final part of this thesis is to study the structure-activity relationship (SAR) between 
readily available HCA analogues chemical structure that are available in ZINC 3D database 
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and to assess its possible anti CETP effects through in vitro study and the possible binding 
site in the CETP tunnel through in-silico study.  
ZINC 3D database, the web accessible chemical structure 
(http://blaster.docking.org/zinc)(Irwin & Shoichet, 2005) contain over 4.6million 
commercially available structures from over 50 compound vendors. In this part of chapter, 
searching through ZINC 3D database was being employed to see the activity relationship 
based on the structural similarity between HCA analogues and the potential inhibitory effects 
against CETP.  
 
Based on ZINC 3D database, there are 9 analogues structure can be obtained. All of the 
analogues were then being subjected to molecular docking by GLIDE. Only two of the 
analogues are then being tested for structural activity relationship (SAR) study. 
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4.8.1 SAR studies of ZINC1656421 
 
Figure 64 Chemical structure of ZINC1656421 
 
 
 
 
 
Figure 65 3D image of docking between ZINC1656421. The yellow dotted lines shows 
the hydrogen bonding between ZINC1656421 and HIS232 and SER230. 
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Table 12 Docking Score result of ZINC1656421 
GLIDE 
gscore 
 -4.966 
GLIDE 
emodel 
-25.859 
 
 
 
 
Figure 66 2D representation of the ligand-receptor interaction between ZINC1656421 
and residue model obtained from docking using Glide showing hydrogen bonds 
involving backbone atoms (solid purple arrows) and hydrogen bonds involving side-
chain atoms (dashed purple arrows). Polar and hydrophobic residues are depicted with 
light blue and green circles respectively. 
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Based on the docking result from GLIDE, ZINC1656421 does form hydrogen bonding 
towards SER230 and HIS232. And the docking score does show that ZINC1656421 does 
have good binding poses. The best pose and docking score for molecular docking of 
ZINC1656421 to CETP are being summarized in table 12.  The GLIDE g-score reading is -
4.966 and the GLIDE emodel value is -25.859. The GLIDE g-score that is being indicated in 
table 12 above shows the sum of the individual H-bond scores for H-bonds between the 
ligand and given residue. The more negative the score the stronger the H-bonding. Based on 
our results the negative values that was being obtained indicate that the H-bonding between 
ZINC1656421 and CETP is strong. Based on this experiment, multiple poses has been 
generated and GLIDE emodel helps in picking up the ‘best’ pose of a ligand. The results 
obtained in this experiment is the best rank among other poses.  
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4.8.2 SAR studies of ZINC895081 
 
 
Figure 67 Chemical Structure of ZINC895081 
 
 
 
 
 
Figure 68 3D view of docking between ZINC895081 and CETP. The yellow dotted lines 
shows the hydrogen bonding between HIS232 and SER230 
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Table 13 Docking Score result of ZINC895081 
GLIDE gscore -4.732 
GLIDE emodel -26.712 
 
 
 
 
Figure 69 2D representation of the ligand-receptor interaction between ZINC895081 
and residue model obtained from docking using Glide showing hydrogen bonds 
involving backbone atoms (solid purple arrows) and hydrogen bonds involving side-
chain atoms (dashed purple arrows). Polar and hydrophobic residues are depicted with 
light blue and green circles respectively. 
 
 
Hydrogen bonding that shows the stability of the complex also form between HIS232 residue 
and SER230 of CETP towards ZINC895081. The hydrogen bonds form due to the presence 
of hydroxyl group and the dissociate oxygen chain of ZINC895081. The best pose and 
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docking score for molecular docking of ZINC1656421 to CETP are being summarized in 
table 13.  The GLIDE g-score reading is -4.732 and the GLIDE emodel value is -26.712. The 
GLIDE g-score that is being indicated in table 13 above shows the sum of the individual H-
bond scores for H-bonds between the ligand and given residue. The more negative the score 
the stronger the H-bonding. Based on our results the negative values that was being obtained 
indicate that the H-bonding between ZINC895081 and CETP is strong. Based on this 
experiment, multiple poses has been generated and GLIDE emodel helps in picking up the 
‘best’ pose of a ligand. The results obtained in this experiment is the best rank among other 
poses.  
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Two of the analogues that has been generated via ZINC 3D database has been chosen to 
undergo Structural Activity Relationship (SAR) study. Both of this analogues have been 
further tested for their inhibition towards CETP using in-vitro CETP assay. ZINC1656421 is 
also known as potassium hydroxycitrate tribasic monohydrate and ZNC895081 are also 
known as Isocitric acid.  
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Figure 70 Inhibition of CETP activity by ZINC1656421 
 
Based on CETP assay as summarized above, the IC50 obtained for ZINC1656421 
 is 29.87 ± 0.032 uM.  
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Figure 71 Inhibition of CETP activity by ZINC895081 
 
Based on result above, compound 2 does shows inhibition towards CETP activity and the 
IC50 obtained is 35± 0.041uM. 
 
Both of the analogues which are ZINC1656421 and ZINC895081 does shows promising 
results in the inhibition of CETP activity. Both of the analogues does shows promising results 
in the inhibition of CETP activity but the IC50 values are higher than the IC50 of pure 
compound of HCA and from this results suggests that HCA is more potent inhibitor 
compared to ZINC1656421 and ZINC895081. The higher the IC50 values, the less potent the 
inhibitor is. .  This explains that HCA is highly potent due to its properties which is easily 
soluble in water or hygroscopic (Lewis and Neelakantan, 1964) and compared to the other 
two analogues. This property giving HCA extra benefit because the presence of polar amino 
acids in the CETP tunnel which can easily forms strong hydrogen bonding with HCA. This 
further explains why HCA stablely binds to CETP.  
The present results may have important implications for our understanding of the 
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pharmacological mechanisms of HCA and its analogues toward CETP activity and this study 
of structural features of HCA, its analogues and CETP are needed for the design of the new 
leads in the discovery of CETP inhibitor. 
 
SAR knowledge reported herein will help to advance this chemical series further and provide 
template to produce more potent CETP inhibitors. Preliminary evaluations through in-silico 
studies and in vitro studies that the metabolic stability of HCA and its analogues series need 
to be improved via synthesis. Next goal is the conception of improved compounds which 
being obtained through synthesis activity, amenable to in-vivo target evaluation studies.  
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Chapter 5: Conclusion 
The main aim of this project is to assess the inhibitory effect of Malaysian plants on CETP 
activity. It is therefore, concluded from this present study that Malaysian local plant are 
sources for isolation of potential inhibitors of hypercholesterolaemic lowering agent that 
possesses inhibitory effect on CETP. Two different plants have been collected which are 
Garcinia atroviridis and Garcinia parvifolia. These two plants undergo methods of 
extraction and optimization which includes sample preparation for CETP assay. Two novel 
compounds which are clusianone and HCA are then tested on  inhibitory effect against CETP 
activity. Based on the preliminary data obtained through screening of crude extracts, HCA 
were choosen for having an IC50 of  20.07 ± 0.05 μM and this values shows that HCA is 
highly potent inhibitor on CETP activity. The inhibitory effect of HCA has been further 
revalidated using enzyme kinetic study, molecular docking study and molecular dynamic 
study. 
 
HCA inhibition mechanism of action were done through enzyme kinetic study which acts as 
an important indicator to access the specific binding interaction that might be involved. 
Values generated from experimental results and plotted graph suggests that HCA possess 
noncompetitive inhibition characteristic in respect to CETP where Km is unchanged and 
Vmax is increasing as the substrate concentration increases. This very important result proves 
that HCA does possess drug like inhibitory characteristic as torcetrapib.  
 
 
An in silico molecular modeling study further support and validate the assay results by pose 
and binding site validation and measuring the binding interaction between HCA and CETP. 
Our results suggest that HCA does binds to the same sites as torcetrapib in regards of CETP 
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tunnel. Molecular dynamic study has been done as part of this thesis in order to see the 
stability of the HCA-CETP complex in nanosecond time scale. The results obtained through 
this study suggest that the binding of HCA towards CETP is stable via the hydrogen bonds 
that exist at the SER 230 throughout 20ns simulation time.  
 
 
In order to strengthen the results, two analogues of HCA which are being obtained through 
ZINC 3D database has been selected and being further tested their structure-activity 
relationship via molecular docking and CETP assay. The results suggest that HCA is potent 
compared to its analogues due to its properties which exhibit higher water solubility and this 
is strong evidence that HCA is a potent inhibitor as CETP tunnel is highly hydrophobic.  
 
 
This work is mostly pioneering research concerning the interaction of CETP and HCA and 
thus paves the way to extend the scope of computational studies in order to gain a much 
deeper understanding concerning the inhibition of CETP. Overall, this PhD project gives a 
firm foundation for future research regarding HCA inhibition on CETP. 
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Chapter 6: Future Perspectives 
This study has successfully proved that Malaysian local plant as a source for secondary 
metabolites does have the potential ability to inhibit CETP. Hydroxycitric Acid (HCA) that is 
available commercially is surprisingly able to inhibit CETP activity. In order to gain deeper 
understanding regarding the inhibition of HCA against CETP, several recommendation that 
could be carried out to extend this study.  This includes conducting this experiment in in-vivo 
level, synthesis of HCA to produce more potent analogues, and to see the interaction 
mechanism between HCA and CETP via X-ray crystallography. 
 
 
Due to the positive results of inhibition of HCA against CETP in this PhD project, it could be 
extend to validate the HCA inhibition in animal context. This approach is important in order 
to see the efficacy of HCA inhibition in animal physiology. The recent advance in in-vivo 
approach is by using in-vivo molecular imaging system where we can see how does the HCA 
inhibition takes place in animal body enabling more complete understanding of the activity of 
a potential therapeutic. This is one of the interesting breakthrough that we could explore in 
CETP or atherosclerosis research at which we could see how does the interaction of HCA in 
real time imaging. 
 
 
Synthesis approach whether it is total synthesis or semi synthesis is another potential area to 
be explored in CETP research. This can be carried out by synthesizing HCA or other 
potential CETP inhibitor by chemically adjusting the side chains in that active compounds to 
enhance binding affinity towards CETP and thus, increase the inhibitory activity. Hydroxyl 
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and amine group can be added in order to increase the hydrogen bonding between HCA and 
CETP.  
 
 
Another interesting field to explore in the CETP research is X-ray crystallography. This 
enables us to understand the physical relationship between CETP and HCA. X-ray 
crystallography is one of the powerful techniques to gain significant understanding of the 
mechanism of inhibition by HCA at protein level. This approach can be used to involve HDL 
particle in order to better clarify the underlying mechanisms behind the inhibitory function of 
the drug. 
 
 
The novel understanding could be used to develop new molecular agents to fight the 
progression of cardiovascular diseases since the existing medicines are not able to prevent all 
cardiovascular events. Overall, this piece of work gives a solid foundation for future research 
projects related to natural product and CETP. 
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APPENDIX A – Parameters for GLIDE  
AI. Table for Protein preparation 
Parameters Action 
Ligands Delete 
Bond order Assign 
Hydrogen Bonds Add 
Zero order bonds to metal Add 
Disulphide bonds Add 
Convert selenomethionines to 
methionines 
Add 
Fill in missing side chains using Prime Add 
Fill in missing loops using Prime Add 
Cap termini Add 
Delete water Add – within 5Å from het groups 
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AII Table for Docking run 
Parameters Action 
Precision SP (standard precision) 
Ligand sampling -Flexible 
-Sample nitrogen inversions 
-sample ring conformations 
Epik state penalties to docking score Add 
Scaling of Van der Waals -Scaling factor : 0.8 
-partial charge cutoff: 0.15 
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APPENDIX B – Parameters for GOLD  
BI Table for parameters for GOLD 
Parameter Action 
Input structure Protein target: 2OBD 
Observed ligands: HCA 
Number of docking: 10 
Early termination settings Allow termination if top 3 solutions are within 
1.5Å RMSD 
Scoring function Chemscore 
GA parameters Population size: 100 
Selection pressure: 1.1 
Number of operations: 30000 
Number of islands: 3 
Niche size: 2 
Migrate 10 
Mutate 95 
Crossover 95 
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APPENDIX C – Parameters for DESMOND 
C1 Table for parameters for protein preparation 
Parameters Action 
Pre-process and analyse structure Assign bond orders 
Add H 
Treat metals 
Delete water : 5Å 
H- bond assignment Sample water orientations 
Impref minimization RMSD (Å) :0.30 
Force field: OPLS 2005 
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Table CII Table for Generation of solvated system 
Parameters actions 
Solvent model SPC 
Boundary conditions Box shape: Orthothombic 
Box size calculation method: Buffer 
Distances (Å): a: 10.0 b:10.0 c: 10.0 
Neutralize system Excluded region: Exclude ion and salt 
placement within 7.0 Å 
Ion placement: Neutralize 
Add salt: Salt concentration = 0.15M 
Salt positive ion : Na+ 
Salt negative ion: Cl- 
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CIII Table for simulation parameters 
Parameters Actions 
Model system Load from workspace : docking model of 
HCA-CETP 
Simulation Simulation time : 20ns, elapsed: 0.0 
Recording interval : 1.0 ps trajectory 20 
Ensemble class: NPT 
Temperature (K) : 300.0 
Pressure bar: 1.01325 
Relax model before simulation: Default 
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APPENDIX D – Number of poses for HCA-CETP docking using GLIDE 
No of poses GLIDE gscore GLIDE gmodel 
1 -4.573 -31.665 
2 -4.436 -31.624 
3 -4.501 -31.621 
4 -4.522 -31.618 
5 -4.516 -31.607 
6 -.4.307 -31.601 
7 -.4.467 -31.596 
8 -4.493 -31.582 
9 -4.512 -31.578 
10 -4.533 -31.563 
11 -4.559 -31.551 
12 -4.413 -31.548 
13 -4.492 -31.541 
14 -4.431 -31.535 
15 -4.215 -31.501 
16 -4.390 -31.492 
17 -4.214 -31.484 
18 -4.108 -31.470 
19 -4.215 -31.462 
20 -4.331 -31.458 
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APPENDIX D – Number of poses for HCA-CETP docking using GOLD 
No of poses chemscore Ranking 
1 38.6 1 
2 36.4 2 
3 35.9 3 
4 33.7 4 
5 32.0 5 
6 31.6 6 
7 29.9 7 
8 28.1 8 
9 27.4 9 
10 23.6 10 
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APPENDIX E – Docking results of HCA analogues using ZINC 3D database 
Structure name GLIDE gscore GLIDE gmodel 
ZINC1656421 -4.966 -25.859 
ZINC1656422 -4.907 -24.974 
ZINC1656423 -4.822 -24.550 
ZINC1656424 -4.806 -22.568 
ZINC895175 -4.902 -22.957 
ZINC895081 -4.732 -26.712 
ZINC895176 -4.686 -30.467 
ZINC895179 -4.878 -24.131 
ZINC895180 -4.754 -21.725 
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APPENDIX F – Publication 
 
 
 
 
